ASTRAZENECA PLC SEC EDGAR Filings (CIK 0000901832)

SEC EDGAR filings, ownership reports, and insider transactions for ASTRAZENECA PLC.

Symbol
AZN on Nasdaq, AZNCF on OTC
Industry
Pharmaceutical Preparations (Office Of Life Sciences)
Business address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA
Top holdings (Schedule 13D)
CLLS and Innate Pharma SA
Top holdings (Schedule 13G)
MNPR and CDT
State of incorporation
United Kingdom
Fiscal year end
31 December
Former names
ZENECA GROUP PLC (to 05 Feb 1999)
⭐ Add to watchlist ⭐
ASTRAZENECA PLC has filed 1,952 SEC EDGAR filings since 13 Mar 1995

Latest Filings

Recent SEC filings for ASTRAZENECA PLC including 6-K, SCHEDULE 13G/A, SCHEDULE 13D/A and more.

Form type Document Filing Description Filing date Reporting date File number(s)
6-K Open 6-K document View SEC filing for 6-K FINAL RESULTS 10 Feb 2026 10 Feb 2026 001-11960
SCHEDULE 13G/A Open SCHEDULE 13G/A document View SEC filing for SCHEDULE 13G/A 06 Feb 2026
SCHEDULE 13D/A Open SCHEDULE 13D/A document View SEC filing for SCHEDULE 13D/A 06 Feb 2026
6-K Open 6-K document View SEC filing for 6-K UPDATE ON SAPHNELO SUBCUTANEOUS ADMINISTRATION 03 Feb 2026 03 Feb 2026 001-11960
S-8 Open S-8 document | Open XBRL data View SEC filing for S-8 FORM S-8 02 Feb 2026 333-293157
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 02 Feb 2026 02 Feb 2026 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI RECOMMENDED IN EU FOR EARLY GASTRIC CANCER 02 Feb 2026 02 Feb 2026 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA BEGINS TRADING ON NYSE 02 Feb 2026 02 Feb 2026 001-11960
25 Open 25 document View SEC filing for 25 FORM 25 30 Jan 2026 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA AGREES OBESITY AND T2D DEAL WITH CSPC 30 Jan 2026 30 Jan 2026 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA INVESTS $15BN IN CHINA THROUGH 2030 29 Jan 2026 29 Jan 2026 001-11960
CERT Open CERT document View SEC filing for CERT NYSE CERTIFICATION 22 Jan 2026 001-11960
8-A12B Open 8-A12B document View SEC filing for 8-A12B 8-A12B 22 Jan 2026 001-11960
CERT Open CERT document View SEC filing for CERT NYSE CERTIFICATION 22 Jan 2026 001-11960
8-A12B Open 8-A12B document View SEC filing for 8-A12B 8-A12B 22 Jan 2026 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA TO COMPLETE DIRECT LISTING ON NYSE 20 Jan 2026 20 Jan 2026 001-11960
6-K Open 6-K document View SEC filing for 6-K AZN NEW HEAD OF INVESTOR RELATIONS JORIS SILON 08 Jan 2026 08 Jan 2026 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 02 Jan 2026 02 Jan 2026 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 22 Dec 2025 22 Dec 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU GRANTED BTD FOR POST-NEOADJUVANT EARLY BC 22 Dec 2025 22 Dec 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K UPDATE ON LATIFY PHASE III TRIAL OF CERALASERTIB 22 Dec 2025 22 Dec 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 19 Dec 2025 19 Dec 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K SUBCUTANEOUS SAPHNELO APPROVED IN EU 16 Dec 2025 16 Dec 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU APPROVED IN US FOR 1L HER2+ METASTATIC BC 16 Dec 2025 16 Dec 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K HOLDING(S) IN COMPANY 04 Dec 2025 04 Dec 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K BLOCK LISTING INTERIM REVIEW 01 Dec 2025 01 Dec 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Dec 2025 01 Dec 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI APPROVED IN US FOR EARLY GASTRIC CANCER 26 Nov 2025 26 Nov 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA MANUFACTURING INVESTMENT IN MARYLAND 24 Nov 2025 24 Nov 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K KOSELUGO (SELUMETINIB) APPROVED IN THE US 20 Nov 2025 20 Nov 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K HOLDING(S) IN COMPANY 17 Nov 2025 17 Nov 2025 001-11960
25-NSE Open 25-NSE document View SEC filing for 25-NSE 14 Nov 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 14 Nov 2025 14 Nov 2025 001-11960
144 Open 144 document View SEC filing for 144 12 Nov 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 10 Nov 2025 10 Nov 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K 9M AND Q3 2025 RESULTS 06 Nov 2025 06 Nov 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K RESULT OF GENERAL MEETING 03 Nov 2025 03 Nov 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 03 Nov 2025 03 Nov 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K FORM 6-K 03 Nov 2025 03 Nov 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR DECLARATION 28 Oct 2025 28 Oct 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K KOSELUGO (SELUMETINIB) APPROVED IN THE EU 28 Oct 2025 28 Oct 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K TEZSPIRE APPROVED IN EU FOR CRSWNP 22 Oct 2025 22 Oct 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K US FDA APPROVES TEZSPIRE IN CRSWNP 20 Oct 2025 20 Oct 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K POSITIVE CHMP OPINION FOR SUBCUTANEOUS SAPHNELO 20 Oct 2025 20 Oct 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K AGREEMENT WITH US GOVT TO LOWER MEDICINE PRICES 14 Oct 2025 14 Oct 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K BAXDROSTAT MET PRIMARY ENDPOINT IN BAX24 PH3 TRIAL 07 Oct 2025 07 Oct 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K DATROWAY IMPROVED OS AND PFS IN TROPION-BREAST02 06 Oct 2025 06 Oct 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Oct 2025 01 Oct 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU IMPROVED IDFS IN EARLY BC IN DB-05 29 Sep 2025 29 Sep 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K AZN HARMONISES LISTING STRUCTURE 29 Sep 2025 29 Sep 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K 6-K 29 Sep 2025 29 Sep 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 25 Sep 2025 25 Sep 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K KOSELUGO RECOMMENDED FOR EU APPROVAL 22 Sep 2025 22 Sep 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K TEZSPIRE RECOMMENDED FOR APPROVAL IN EU FOR CRSWNP 22 Sep 2025 22 Sep 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K SAPHNELO MET PRIMARY ENDPOINT IN TULIP-SC 17 Sep 2025 17 Sep 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K UPDATE ON RESOLUTE PHASE III TRIAL 17 Sep 2025 17 Sep 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 02 Sep 2025 02 Sep 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K HOLDING(S) IN COMPANY 28 Aug 2025 28 Aug 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K HOLDING(S) IN COMPANY 26 Aug 2025 26 Aug 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K HOLDING(S) IN COMPANY 21 Aug 2025 21 Aug 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 18 Aug 2025 18 Aug 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K HOLDING(S) IN COMPANY 15 Aug 2025 15 Aug 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K HOLDING(S) IN COMPANY 12 Aug 2025 12 Aug 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Aug 2025 01 Aug 2025 001-11960
6-K Open 6-K document | Open XBRL data View SEC filing for 6-K FORM 6-K 29 Jul 2025 30 Jun 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K GEFURULIMAB NANOBODY MET PHASE III ENDPOINTS 24 Jul 2025 24 Jul 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA PLANS TO INVEST $50BN IN THE US 22 Jul 2025 22 Jul 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K UPDATE ON ANSELAMIMAB IN AL AMYLOIDOSIS 16 Jul 2025 16 Jul 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K BAXDROSTAT MET PRIMARY ENDPT IN BAXHTN PHIII TRIAL 14 Jul 2025 14 Jul 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI APPROVED IN THE EU FOR BLADDER CANCER 07 Jul 2025 07 Jul 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Jul 2025 01 Jul 2025 001-11960
11-K Open 11-K document View SEC filing for 11-K FORM 11-K 26 Jun 2025 31 Dec 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K DATROWAY APPROVED IN US FOR EGFRM LUNG CANCER 24 Jun 2025 24 Jun 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA ENTERS INTO COLLABORATION WITH CSPC 13 Jun 2025 13 Jun 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 12 Jun 2025 12 Jun 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K FIXED-DURATION CALQUENCE APPROVED IN EU FOR 1L CLL 06 Jun 2025 06 Jun 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K BLOCK LISTING INTERIM REVIEW 02 Jun 2025 02 Jun 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 02 Jun 2025 02 Jun 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI RECOMMENDED IN EU FOR BLADDER CANCER 27 May 2025 27 May 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 23 May 2025 23 May 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR DECLARATION 21 May 2025 21 May 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K ACQUISITION OF ESOBIOTEC COMPLETED 20 May 2025 20 May 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI IMPROVED DFS IN EARLY BLADDER CANCER 09 May 2025 09 May 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU IMPROVED PCR IN EARLY-STAGE BREAST CANCER 07 May 2025 07 May 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K CALQUENCE COMBINATION APPROVED IN EU FOR 1L MCL 06 May 2025 06 May 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K BREZTRI MET PRIMARY ENDPOINTS IN PH3 ASTHMA TRIALS 02 May 2025 02 May 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 01 May 2025 01 May 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 May 2025 01 May 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K FIXED-DURATION CALQUENCE RECOMMENDED IN EU FOR CLL 29 Apr 2025 29 Apr 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K UPDATE ON CAPITELLO-280 PHASE III TRIAL 29 Apr 2025 29 Apr 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K 1ST QUARTER RESULTS 29 Apr 2025 29 Apr 2025 001-11960
SCHEDULE 13G/A Open SCHEDULE 13G/A document View SEC filing for SCHEDULE 13G/A 23 Apr 2025 005-55247
6-K Open 6-K document View SEC filing for 6-K ENHERTU COMBINATION IMPROVED PFS IN 1L HER2+ MBC 22 Apr 2025 22 Apr 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K RESULT OF AGM 11 Apr 2025 11 Apr 2025 001-11960
SCHEDULE 13G/A Open SCHEDULE 13G/A document View SEC filing for SCHEDULE 13G/A 10 Apr 2025
6-K Open 6-K document View SEC filing for 6-K IMFINZI APPROVED IN EU FOR AEGEAN 04 Apr 2025 04 Apr 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU APPROVED IN EU IN POST-ET BREAST CANCER 04 Apr 2025 04 Apr 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Apr 2025 01 Apr 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K CALQUENCE RECOMMENDED FOR EU APPROVAL IN 1L MCL 31 Mar 2025 31 Mar 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI APPROVED IN THE US FOR BLADDER CANCER 31 Mar 2025 31 Mar 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K AZN INVESTS $2.5BN IN BEIJING R&D & MANUFACTURING 21 Mar 2025 21 Mar 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K ENEBOPARATIDE PHASE III TRIAL MET PRIMARY ENDPOINT 17 Mar 2025 17 Mar 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI APPROVED IN EU FOR LIMITED-STAGE SCLC 17 Mar 2025 17 Mar 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA TO ACQUIRE ESOBIOTEC 17 Mar 2025 17 Mar 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K HOLDING(S) IN COMPANY 12 Mar 2025 12 Mar 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 07 Mar 2025 07 Mar 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K NOTICE OF AGM 07 Mar 2025 07 Mar 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI IMPROVED EFS IN EARLY-STAGE GASTRIC CANCER 07 Mar 2025 07 Mar 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K FORM 6-K 07 Mar 2025 07 Mar 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 06 Mar 2025 06 Mar 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 05 Mar 2025 05 Mar 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 03 Mar 2025 03 Mar 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI RECOMMENDED FOR EU APPROVAL FOR AEGEAN 03 Mar 2025 03 Mar 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU RECOMMENDED IN EU IN POST-ET BREAST CANCER 28 Feb 2025 28 Feb 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K CAMIZESTRANT IMPROVED PFS IN 1L HR+ BREAST CANCER 26 Feb 2025 26 Feb 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K FILING OF FORM 20-F WITH SEC 19 Feb 2025 19 Feb 2025 001-11960
IRANNOTICE Open IRANNOTICE document View SEC filing for IRANNOTICE IRANNOTICE 18 Feb 2025 001-11960
20-F Open 20-F document | Open XBRL data View SEC filing for 20-F FORM 20-F 18 Feb 2025 31 Dec 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K FORM 6-K 18 Feb 2025 18 Feb 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K HOLDING(S) IN COMPANY 18 Feb 2025 18 Feb 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K ANNUAL FINANCIAL REPORT 18 Feb 2025 18 Feb 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTORATE CHANGE 18 Feb 2025 18 Feb 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K FINAL RESULTS 06 Feb 2025 06 Feb 2025 001-11960
EFFECT Open EFFECT document View SEC filing for EFFECT 05 Feb 2025 333-284374
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 03 Feb 2025 03 Feb 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI RECOMMENDED FOR EU APPROVAL FOR LS-SCLC 03 Feb 2025 03 Feb 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU APPROVED IN US FOR BREAST CANCER POST ET 28 Jan 2025 28 Jan 2025 001-11960
SCHEDULE 13D/A Open SCHEDULE 13D/A document View SEC filing for SCHEDULE 13D/A 24 Jan 2025
F-6 Open F-6 document View SEC filing for F-6 21 Jan 2025 333-284374
6-K Open 6-K document View SEC filing for 6-K DATO-DXD APPROVED IN US FOR HR+ BREAST CANCER 21 Jan 2025 21 Jan 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K CALQUENCE COMBINATION APPROVED IN US FOR 1L MCL 17 Jan 2025 17 Jan 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 02 Jan 2025 02 Jan 2025 001-11960
6-K Open 6-K document View SEC filing for 6-K DATO-DXD NSQ NSCLC APPLICATION WITHDRAWN IN EU 26 Dec 2024 26 Dec 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K TAGRISSO APPROVED IN EU BASED ON LAURA TRIAL 23 Dec 2024 23 Dec 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTORATE CHANGE 16 Dec 2024 16 Dec 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI APPROVED IN US FOR LIMITED-STAGE SCLC 05 Dec 2024 05 Dec 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA APPOINTS ISKRA REIC EVP INTERNATIONAL 04 Dec 2024 04 Dec 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K BLOCK LISTING INTERIM REVIEW 02 Dec 2024 02 Dec 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 02 Dec 2024 02 Dec 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K TRUQAP IMPROVED RPFS IN ADVANCED PROSTATE CANCER 25 Nov 2024 25 Nov 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 20 Nov 2024 20 Nov 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K TAGRISSO RECOMMENDED FOR EU APPROVAL - LAURA 18 Nov 2024 18 Nov 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 15 Nov 2024 15 Nov 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 15 Nov 2024 15 Nov 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 Nov 2024 13 Nov 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA INVESTS $3.5 BILLION IN US 12 Nov 2024 12 Nov 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K KOMET PHASE III TRIAL MET PRIMARY ENDPOINT 12 Nov 2024 12 Nov 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K 9M AND Q3 2024 RESULTS 12 Nov 2024 12 Nov 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K DATO-DXD NEW BLA SUBMITTED, NSQ BLA WITHDRAWN 12 Nov 2024 12 Nov 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K TEZSPIRE NASAL POLYPS TRIAL MET PRIMARY ENDPOINTS 08 Nov 2024 08 Nov 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Nov 2024 01 Nov 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K AZN CHINA PRESIDENT UNDER INVESTIGATION 30 Oct 2024 30 Oct 2024 001-11960
SC 13G Open SC 13G document View SEC filing for SC 13G SC 13G 28 Oct 2024
6-K Open 6-K document View SEC filing for 6-K FORM 6-K 21 Oct 2024 21 Oct 2024 001-11960
SC 13G Open SC 13G document View SEC filing for SC 13G SC 13G 11 Oct 2024
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA LICENSES LIPID LOWERING LP(A) ASSET 07 Oct 2024 07 Oct 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Oct 2024 01 Oct 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K TAGRISSO US APPROVAL IN UNRESECTABLE LUNG CANCER 26 Sep 2024 26 Sep 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K FASENRA RECOMMENDED FOR EU APPROVAL IN EGPA 23 Sep 2024 23 Sep 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K FINAL OS RESULTS REPORTED FOR TROPION - BREAST01 23 Sep 2024 23 Sep 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K FLUMIST APPROVED FOR SELF-ADMINISTRATION IN US 20 Sep 2024 20 Sep 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K FASENRA EGPA US FDA APPROVAL 18 Sep 2024 18 Sep 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 Sep 2024 13 Sep 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 03 Sep 2024 02 Sep 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI APPROVED IN US FOR RESECTABLE LUNG CANCER 16 Aug 2024 16 Aug 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Aug 2024 01 Aug 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA PRICES A EUR1.4BN BOND OFFERING 30 Jul 2024 30 Jul 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K CALQUENCE FIXED-DURATION COMBO IMPROVED 1L CLL PFS 29 Jul 2024 29 Jul 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K ODAC REVIEWED IMFINZI IN RESECTABLE LUNG CANCER 26 Jul 2024 26 Jul 2024 001-11960
6-K Open 6-K document | Open XBRL data View SEC filing for 6-K FORM 6K 25 Jul 2024 30 Jun 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K ACQUISITION OF AMOLYT PHARMA COMPLETED 15 Jul 2024 15 Jul 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Jul 2024 01 Jul 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA & IMFINZI POSITIVE CHMP IN ENDOMETRIAL 01 Jul 2024 01 Jul 2024 001-11960
11-K Open 11-K document View SEC filing for 11-K ANNUAL REPORT 26 Jun 2024 31 Dec 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K UPDATE ON IMFINZI ADJUVANT BR.31 TRIAL 25 Jun 2024 25 Jun 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI IMPROVED EFS AND OS IN BLADDER CANCER 25 Jun 2024 25 Jun 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K UPDATE ON CAPITELLO-290 PHASE III TRIAL 18 Jun 2024 18 Jun 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI APPROVED IN THE US FOR ENDOMETRIAL CANCER 17 Jun 2024 17 Jun 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 12 Jun 2024 12 Jun 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K FORM 6-K 04 Jun 2024 04 Jun 2024 001-11960
25-NSE Open 25-NSE document View SEC filing for 25-NSE 04 Jun 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K BLOCK LISTING INTERIM REVIEW 03 Jun 2024 03 Jun 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 03 Jun 2024 03 Jun 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K TAGRISSO PLUS CHEMO RECOMMENDED FOR APPROVAL IN EU 03 Jun 2024 03 Jun 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K DATO-DXD IMPROVED OS IN NONSQUAMOUS LUNG CANCER 28 May 2024 28 May 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA TO DELIVER $80BN REVENUE BY 2030 21 May 2024 21 May 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA TO MANUFACTURE ADCS IN SINGAPORE 20 May 2024 20 May 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K SUPERNOVA TRIAL MET COVID-19 PREVENTION ENDPOINT 16 May 2024 16 May 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 15 May 2024 15 May 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA COMPLETES CELLECTIS EQUITY INVESTMENT 07 May 2024 07 May 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K CALQUENCE COMBINATION IMPROVED PFS IN 1L MCL 02 May 2024 02 May 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 May 2024 01 May 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K TRUQAP RECOMMENDED FOR EU BREAST CANCER APPROVAL 29 Apr 2024 29 Apr 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU IMPROVED PFS IN HER2-LOW AND ULTRALOW 29 Apr 2024 29 Apr 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K 1ST QUARTER RESULTS 25 Apr 2024 25 Apr 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K RESULT OF AGM 11 Apr 2024 11 Apr 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA INCREASES 2024 DIVIDEND BY 7% 11 Apr 2024 11 Apr 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU APPROVED IN US FOR HER2+ SOLID TUMOURS 08 Apr 2024 08 Apr 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI IMPROVED OS & PFS IN LIMITED-STAGE SCLC 05 Apr 2024 05 Apr 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 02 Apr 2024 02 Apr 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K VOYDEYA APPROVED IN US 02 Apr 2024 02 Apr 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K FDA ACCEPTS DATO-DXD BLA FOR BREAST CANCER 02 Apr 2024 02 Apr 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K ULTOMIRIS APPROVED IN THE US FOR NMOSD 25 Mar 2024 25 Mar 2024 001-11960
DFAN14A Open DFAN14A document View SEC filing for DFAN14A DFAN14A 19 Mar 2024
F-3ASR Open F-3ASR document View SEC filing for F-3ASR F-3ASR 19 Mar 2024 333-278067
6-K Open 6-K document View SEC filing for 6-K FORM 6-K 19 Mar 2024 19 Mar 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA TO ACQUIRE AMOLYT 14 Mar 2024 14 Mar 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 12 Mar 2024 12 Mar 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K FORM 6-K 07 Mar 2024 07 Mar 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K NOTICE OF AGM 07 Mar 2024 07 Mar 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 06 Mar 2024 06 Mar 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 06 Mar 2024 06 Mar 2024 001-11960
CERT Open CERT document View SEC filing for CERT 06 Mar 2024 001-11960
8-A12B Open 8-A12B document View SEC filing for 8-A12B 8-A12B 05 Mar 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K EMA VALIDATES DATO-DXD MAAS FOR NSQ NSCLC AND BC 04 Mar 2024 04 Mar 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Mar 2024 01 Mar 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K FORM 6-K 26 Feb 2024 26 Feb 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K VOYDEYA RECOMMENDED FOR EU APPROVAL 26 Feb 2024 26 Feb 2024 001-11960
424B2 Open 424B2 document View SEC filing for 424B2 424B2 23 Feb 2024 333-256406
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA PRICES A $5BN BOND OFFERING 22 Feb 2024 22 Feb 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K FORM 6-K 22 Feb 2024 22 Feb 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 22 Feb 2024 22 Feb 2024 001-11960
FWP Open FWP document View SEC filing for FWP FWP 22 Feb 2024 333-256406
SC TO-T/A Open SC TO-T/A document View SEC filing for SC TO-T/A SC TO-T/A 21 Feb 2024
424B2 Open 424B2 document View SEC filing for 424B2 424B2 21 Feb 2024 333-256406
6-K Open 6-K document View SEC filing for 6-K FILING OF FORM 20-F WITH SEC 21 Feb 2024 21 Feb 2024 001-11960
S-8 Open S-8 document View SEC filing for S-8 FORM S-8 20 Feb 2024 333-277197
IRANNOTICE Open IRANNOTICE document View SEC filing for IRANNOTICE IRANNOTICE 20 Feb 2024 001-11960
20-F Open 20-F document | Open XBRL data View SEC filing for 20-F FORM 20-F 20 Feb 2024 31 Dec 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K FORM 6-K 20 Feb 2024 20 Feb 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K ANNUAL FINANCIAL REPORT 20 Feb 2024 20 Feb 2024 001-11960
SC TO-T/A Open SC TO-T/A document View SEC filing for SC TO-T/A SC TO-T/A 20 Feb 2024
6-K Open 6-K document View SEC filing for 6-K FORM 6-K 20 Feb 2024 20 Feb 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA COMPLETES ACQUISITION OF ICOSAVAX 20 Feb 2024 20 Feb 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K TAGRISSO PLUS CHEMO APPROVED IN US FOR LUNG CANCER 20 Feb 2024 20 Feb 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K FDA ACCEPTS DATO-DXD BLA FOR NONSQUAMOUS NSCLC 20 Feb 2024 20 Feb 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K TAGRISSO IMPROVED PFS IN STAGE III LUNG CANCER 20 Feb 2024 19 Feb 2024 001-11960
SC TO-T/A Open SC TO-T/A document View SEC filing for SC TO-T/A SC TO-T/A 15 Feb 2024
SC 13G/A Open SC 13G/A document View SEC filing for SC 13G/A SC 13G/A 12 Feb 2024
6-K Open 6-K document View SEC filing for 6-K FINAL RESULTS 08 Feb 2024 08 Feb 2024 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Feb 2024 01 Feb 2024 001-11960
SC 13G/A Open SC 13G/A document View SEC filing for SC 13G/A 24 Jan 2024 005-55247
SC TO-T/A Open SC TO-T/A document View SEC filing for SC TO-T/A SC TO-T/A 19 Jan 2024
6-K Open 6-K document View SEC filing for 6-K FORM 6-K 19 Jan 2024 19 Jan 2024 001-11960
SC TO-T/A Open SC TO-T/A document View SEC filing for SC TO-T/A SC TO-T/A 11 Jan 2024
CORRESP Open CORRESP document View SEC filing for CORRESP 10 Jan 2024
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 02 Jan 2024 02 Jan 2024 001-11960
SC TO-T Open SC TO-T document View SEC filing for SC TO-T SC TO-T 27 Dec 2023
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA ACQUIRES GRACELL 27 Dec 2023 27 Dec 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K FORM 6-K 26 Dec 2023 26 Dec 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K WAINUA (EPLONTERSEN) GRANTED FIRST US FDA APPROVAL 22 Dec 2023 22 Dec 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 14 Dec 2023 14 Dec 2023 001-11960
SC TO-C Open SC TO-C document View SEC filing for SC TO-C SC TO-C 12 Dec 2023
6-K Open 6-K document View SEC filing for 6-K FORM 6-K 12 Dec 2023 12 Dec 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA TO ACQUIRE ICOSAVAX 12 Dec 2023 12 Dec 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K BLOCK LISTING INTERIM REVIEW 01 Dec 2023 01 Dec 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Dec 2023 01 Dec 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K DISCONTINUATION OF TWO CRYSTALIZE EVIDENCE TRIALS 01 Dec 2023 01 Dec 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 24 Nov 2023 24 Nov 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K TRUQAP APPROVED IN US FOR HR+ BREAST CANCER 17 Nov 2023 17 Nov 2023 001-11960
SC 13D/A Open SC 13D/A document View SEC filing for SC 13D/A SC 13D/A 16 Nov 2023
25-NSE Open 25-NSE document View SEC filing for 25-NSE 14 Nov 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K UPDATE ON PACIFIC-2 PHASE III TRIAL FOR IMFINZI 14 Nov 2023 14 Nov 2023 001-11960
144 Open 144 document View SEC filing for 144 13 Nov 2023 001-11960
SC 13D Open SC 13D document View SEC filing for SC 13D SC 13D 09 Nov 2023
6-K Open 6-K document View SEC filing for 6-K DIRECTOR DECLARATION 09 Nov 2023 09 Nov 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI COMBINATION IMPROVES PFS IN LIVER CANCER 09 Nov 2023 09 Nov 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K AGREEMENT WITH ECCOGENE FOR CLINICAL STAGE GLP-1RA 09 Nov 2023 09 Nov 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K 9M AND Q3 2023 RESULTS 09 Nov 2023 02 Nov 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Nov 2023 01 Nov 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA CELL & GENE THERAPY DEAL W/ CELLECTIS 01 Nov 2023 01 Nov 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA SETTLES NEXIUM LIABILITY LITIGATIONS 03 Oct 2023 03 Oct 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 02 Oct 2023 02 Oct 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K DATO-DXD IMPROVED PFS IN BREAST CANCER 25 Sep 2023 22 Sep 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K ALEXION COMPLETES PFIZER GENE THERAPY AGREEMENT 20 Sep 2023 20 Sep 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU RECOMMENDED IN EU FOR HER2-MUTANT NSCLC 15 Sep 2023 15 Sep 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K FASENRA PHASE III EGPA TRIAL MET PRIMARY ENDPOINT 11 Sep 2023 11 Sep 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K UPDATE ON US REVIEW OF ULTOMIRIS FOR NMOSD 06 Sep 2023 06 Sep 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Sep 2023 01 Sep 2023 001-11960
25-NSE Open 25-NSE document View SEC filing for 25-NSE 16 Aug 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Aug 2023 01 Aug 2023 001-11960
6-K Open 6-K document | Open XBRL data View SEC filing for 6-K FORM 6K 28 Jul 2023 30 Jun 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K ALEXION ENTERS GENE THERAPY AGREEMENT WITH PFIZER 28 Jul 2023 28 Jul 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K BEYFORTUS APPROVED IN US FOR INFANT RSV PREVENTION 17 Jul 2023 17 Jul 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 03 Jul 2023 03 Jul 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K DATO-DXD SIGNIFICANTLY IMPROVED PFS IN LUNG CANCER 03 Jul 2023 03 Jul 2023 001-11960
11-K Open 11-K document View SEC filing for 11-K ANNUAL REPORT 28 Jun 2023 31 Dec 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K NIRSEVIMAB RECOMMENDED FOR INFANT RSV PROTECTION 09 Jun 2023 09 Jun 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA AGREEMENT WITH QUELL THERAPEUTICS 09 Jun 2023 09 Jun 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI IMPROVED PCR IN GASTRIC AND GEJ CANCERS 02 Jun 2023 02 Jun 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K BLOCK LISTING INTERIM REVIEW 01 Jun 2023 01 Jun 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Jun 2023 01 Jun 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA APPROVED IN US FOR BRCAM PROSTATE CANCER 01 Jun 2023 01 Jun 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI + LYNPARZA PROLONGED PFS IN ENDOMETRIAL CANCER 26 May 2023 26 May 2023 001-11960
25-NSE Open 25-NSE document View SEC filing for 25-NSE 25 May 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTORATE CHANGE 22 May 2023 22 May 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K TAGRISSO PLUS CHEMO IMPROVED PFS IN LUNG CANCER 17 May 2023 17 May 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 09 May 2023 09 May 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K FARXIGA EXTENDED IN THE US FOR HEART FAILURE 09 May 2023 09 May 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 02 May 2023 02 May 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K ODAC VOTE ON LYNPARZA COMBO IN PROSTATE CANCER 02 May 2023 02 May 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 02 May 2023 02 May 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K 1ST QUARTER RESULTS 27 Apr 2023 27 Apr 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K RESULT OF AGM 27 Apr 2023 27 Apr 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K FORM 6-K 27 Apr 2023 27 Apr 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K BOARD COMMITTEE CHANGES 27 Apr 2023 27 Apr 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR DECLARATION 26 Apr 2023 26 Apr 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K UPDATE TO ARRANGEMENTS WITH SOBI AND SANOFI 11 Apr 2023 11 Apr 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA + IMFINZI MET ENDPOINT IN OVARIAN CANCER 05 Apr 2023 05 Apr 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 03 Apr 2023 03 Apr 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K ULTOMIRIS RECOMMENDED FOR NMOSD EU APPROVAL 03 Apr 2023 03 Apr 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA COMPLETES KYM AGREEMENT FOR CMG901 30 Mar 2023 30 Mar 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 27 Mar 2023 27 Mar 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K FORM 6-K 22 Mar 2023 22 Mar 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K NOTICE OF AGM 22 Mar 2023 22 Mar 2023 001-11960
CERT Open CERT document View SEC filing for CERT 15 Mar 2023 001-11960
8-A12B Open 8-A12B document View SEC filing for 8-A12B 8-A12B 13 Mar 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI IMPROVED EFS IN RESECTABLE LUNG CANCER 09 Mar 2023 09 Mar 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 08 Mar 2023 08 Mar 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 08 Mar 2023 08 Mar 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU DESTINY-PANTUMOR02 SHOWS POSITIVE RESULTS 06 Mar 2023 06 Mar 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K FORM 6-K 03 Mar 2023 03 Mar 2023 001-11960
424B2 Open 424B2 document View SEC filing for 424B2 424B2 02 Mar 2023 333-256406
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Mar 2023 01 Mar 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA PRICES A $2.25BN BOND OFFERING 01 Mar 2023 01 Mar 2023 001-11960
FWP Open FWP document View SEC filing for FWP FWP 01 Mar 2023 333-256406
424B2 Open 424B2 document View SEC filing for 424B2 424B2 28 Feb 2023 333-256406
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA PRICES A EUR1.5BN BOND OFFERING 24 Feb 2023 24 Feb 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA ACQUIRES CINCOR FOR CARDIORENAL ASSET 24 Feb 2023 24 Feb 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 24 Feb 2023 24 Feb 2023 001-11960
SC TO-T/A Open SC TO-T/A document View SEC filing for SC TO-T/A SC TO-T/A 24 Feb 2023
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA ENTERS AGREEMENT WITH KYM FOR CMG901 23 Feb 2023 23 Feb 2023 001-11960
SC TO-T/A Open SC TO-T/A document View SEC filing for SC TO-T/A SC TO-T 23 Feb 2023
6-K Open 6-K document View SEC filing for 6-K FILING OF FORM 20-F WITH SEC 22 Feb 2023 22 Feb 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K FORM 6-K 21 Feb 2023 21 Feb 2023 001-11960
IRANNOTICE Open IRANNOTICE document View SEC filing for IRANNOTICE IRANNOTICE 21 Feb 2023 001-11960
20-F Open 20-F document | Open XBRL data View SEC filing for 20-F FORM 20-F 21 Feb 2023 31 Dec 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K ANNUAL FINANCIAL REPORT 21 Feb 2023 21 Feb 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 Feb 2023 13 Feb 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 Feb 2023 13 Feb 2023 001-11960
SC 13G/A Open SC 13G/A document View SEC filing for SC 13G/A SC 13G/A 10 Feb 2023
SC 13G/A Open SC 13G/A document View SEC filing for SC 13G/A SC 13G/A 10 Feb 2023
6-K Open 6-K document View SEC filing for 6-K FINAL RESULTS 09 Feb 2023 09 Feb 2023 001-11960
SC TO-T/A Open SC TO-T/A document View SEC filing for SC TO-T/A SC TO-T/A 03 Feb 2023
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Feb 2023 01 Feb 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K UPDATE ON EVUSHELD US EUA 26 Jan 2023 26 Jan 2023 001-11960
SC 13G/A Open SC 13G/A document View SEC filing for SC 13G/A 24 Jan 2023 005-55247
SC TO-T Open SC TO-T document View SEC filing for SC TO-T SC TO-T 23 Jan 2023
6-K Open 6-K document View SEC filing for 6-K ACQUISITION OF NEOGENE THERAPEUTICS COMPLETED 17 Jan 2023 17 Jan 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K AIRSUPRA (PT027) APPROVED IN US FOR ASTHMA 11 Jan 2023 11 Jan 2023 001-11960
SC TO-C Open SC TO-C document View SEC filing for SC TO-C SC TO-C 09 Jan 2023
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA ACQUIRE CINCOR FOR CARDIORENAL ASSET 09 Jan 2023 09 Jan 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 03 Jan 2023 03 Jan 2023 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 30 Dec 2022 30 Dec 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K CALQUENCE JAPAN APPROVAL FOR TREATMENT-NAIVE CLL 28 Dec 2022 28 Dec 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI, IMJUDO APPROVED IN JAPAN FOR 3 CANCERS 28 Dec 2022 28 Dec 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI APPROVED IN EU FOR BILIARY TRACT CANCER 21 Dec 2022 21 Dec 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA APPROVED IN EU FOR PROSTATE CANCER 21 Dec 2022 21 Dec 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR PATIENTS WITH HER2-LOW ME 19 Dec 2022 19 Dec 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU APPROVED IN THE EU FOR PATIENTS WITH PREVIOUSLY TREATED HER2-POSITIVE AD 19 Dec 2022 19 Dec 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI PLUS IMJUDO RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR THE TREATMENT 19 Dec 2022 19 Dec 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K UPDATE ON PEARL PHASE III TRIAL OF IMFINZI MONOTHERAPY IN STAGE IV NON-SMALL CEL 19 Dec 2022 19 Dec 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K FORXIGA CHMP OPINION FOR SYMPTOMATIC CHRONIC HF 19 Dec 2022 19 Dec 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K UPDATE ON US REVIEW OF LYNPARZA PROPEL SNDA 15 Dec 2022 15 Dec 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K CAPIVASERTIB PFS IN HR-POSITIVE BREAST CANCER 08 Dec 2022 08 Dec 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Dec 2022 01 Dec 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K BLOCK LISTING INTERIM REVIEW 01 Dec 2022 01 Dec 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA ANNOUNCES SALE OF WEST CHESTER SITE 30 Nov 2022 30 Nov 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA TO ACQUIRE NEOGENE THERAPEUTICS 29 Nov 2022 29 Nov 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 23 Nov 2022 23 Nov 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU RECOMMENDED FOR EU APPROVAL IN GASTRIC 14 Nov 2022 14 Nov 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI RECOMMENDED FOR APPROVAL IN THE EU FOR BTC 14 Nov 2022 14 Nov 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA COMBO RECOMMENDED IN THE EU FOR MCRPC 14 Nov 2022 14 Nov 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI + IMJUDO APPROVED IN US FOR LUNG CANCER 14 Nov 2022 11 Nov 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K YTD AND Q3 2022 RESULTS 10 Nov 2022 10 Nov 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K FDA ADVISORY COMMITTEE RECOMMENDS PT027 IN ASTHMA 09 Nov 2022 09 Nov 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K BEYFORTUS (NIRSEVIMAB) APPROVED IN EU 04 Nov 2022 04 Nov 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Nov 2022 01 Nov 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K CAPIVASERTIB PHASE III TRIAL MET PRIMARY ENDPOINTS 26 Oct 2022 26 Oct 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K UPDATE ON MESSINA PHASE III TRIAL 25 Oct 2022 25 Oct 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI + IMJUDO APPROVED IN ADVANCED LIVER CANCER 24 Oct 2022 24 Oct 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 03 Oct 2022 03 Oct 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K BOARD COMMITTEE CHANGES 30 Sep 2022 30 Sep 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K KOSELUGO APPROVED IN JAPAN FOR NF1 27 Sep 2022 27 Sep 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K TEZSPIRE APPROVED IN JAPAN FOR SEVERE ASTHMA 27 Sep 2022 27 Sep 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K ULTOMIRIS APPROVED IN EU FOR GMG 23 Sep 2022 23 Sep 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA APPROVED IN CHINA FOR OVARIAN CANCER 22 Sep 2022 22 Sep 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K TEZSPIRE APPROVED IN THE EU FOR SEVERE ASTHMA 21 Sep 2022 21 Sep 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K EVUSHELD APPROVED IN EU FOR COVID-19 TREATMENT 20 Sep 2022 20 Sep 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K DANICOPAN PHASE III TRIAL MET PRIMARY ENDPOINT 16 Sep 2022 16 Sep 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K NIRSEVIMAB RECOMMENDED FOR APPROVAL IN EU BY CHMP 16 Sep 2022 16 Sep 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K EVUSHELD POSITIVE CHMP OPINION IN EU 16 Sep 2022 16 Sep 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K FORXIGA APPROVED IN CHINA FOR CKD 06 Sep 2022 06 Sep 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI APPROVED IN US FOR BILIARY TRACT CANCER 06 Sep 2022 06 Sep 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Sep 2022 01 Sep 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K EVUSHELD APPROVED FOR COVID-19 IN JAPAN 30 Aug 2022 30 Aug 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K FARXIGA REDUCED RISK OF CV DEATH OR WORSENING HF 30 Aug 2022 30 Aug 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K FARXIGA SHOWS CV MORTALITY BENEFIT ACROSS EF RANGE 30 Aug 2022 30 Aug 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K ULTOMIRIS APPROVED IN JAPAN FOR GMG 25 Aug 2022 25 Aug 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K TAGRISSO APPROVED IN JAPAN FOR EARLY LUNG CANCER 25 Aug 2022 25 Aug 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA APPROVED IN JAPAN FOR EARLY BREAST CANCER 25 Aug 2022 25 Aug 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA GRANTED FDA PRIORITY REVIEW FOR PROPEL 16 Aug 2022 16 Aug 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU IMPROVED PFS IN MBC IN DESTINY-BREAST02 15 Aug 2022 15 Aug 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU APPROVED IN US FOR HER2-MUTANT NSCLC 12 Aug 2022 12 Aug 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K ACQUISITION OF TENEOTWO COMPLETED 11 Aug 2022 11 Aug 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU APPROVED IN THE US FOR HER2-LOW MBC 08 Aug 2022 08 Aug 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA APPROVED IN EU FOR EARLY BREAST CANCER 04 Aug 2022 04 Aug 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 01 Aug 2022 01 Aug 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Aug 2022 01 Aug 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 01 Aug 2022 01 Aug 2022 001-11960
6-K Open 6-K document | Open XBRL data View SEC filing for 6-K FORM 6-K 29 Jul 2022 30 Jun 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K CHAIR SUCCESSION 29 Jul 2022 29 Jul 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K TEZSPIRE RECOMMENDED FOR EU APPROVAL IN ASTHMA 25 Jul 2022 25 Jul 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K ULTOMIRIS RECOMMENDED FOR EU APPROVAL FOR GMG 25 Jul 2022 25 Jul 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU GRANTED PRIORITY REVIEW FOR HER2-LOW MBC 25 Jul 2022 25 Jul 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU APPROVED IN EU FOR HER2-POSITIVE MBC 19 Jul 2022 19 Jul 2022 001-11960
SC 13G Open SC 13G document View SEC filing for SC 13G 08 Jul 2022 005-55247
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA TO ACQUIRE TENEOTWO AND T CELL ENGAGER 05 Jul 2022 05 Jul 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Jul 2022 01 Jul 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI IMPROVED PCR IN RESECTABLE LUNG CANCER 30 Jun 2022 30 Jun 2022 001-11960
11-K Open 11-K document View SEC filing for 11-K ANNUAL REPORT 29 Jun 2022 31 Dec 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU RECOMMENDED FOR BREAST CANCER EU APPROVAL 27 Jun 2022 27 Jun 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA RECOMMENDED IN EU FOR EARLY BREAST CANCER 27 Jun 2022 27 Jun 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K EPLONTERSEN PH III TRIAL MET CO-PRIMARY ENDPOINTS 21 Jun 2022 21 Jun 2022 001-11960
25-NSE Open 25-NSE document View SEC filing for 25-NSE 10 Jun 2022 001-11960
25-NSE Open 25-NSE document View SEC filing for 25-NSE 09 Jun 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU EFFICACY RESULTS IN HER2-LOW BREAST CANCER 06 Jun 2022 06 Jun 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K BLOCK LISTING INTERIM REVIEW 01 Jun 2022 01 Jun 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Jun 2022 01 Jun 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 20 May 2022 20 May 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K APPOINTMENT OF JOINT CORPORATE BROKERS 09 May 2022 09 May 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 06 May 2022 06 May 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU APPROVED IN US FOR 2L HER2+ BREAST CANCER 05 May 2022 05 May 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K FARXIGA HFPEF PHASE III TRIAL MET PRIMARY ENDPOINT 05 May 2022 05 May 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K ULTOMIRIS NMOSD PH. III TRIAL MET PRIMARY ENDPOINT 05 May 2022 05 May 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI COMBO GRANTED PRIORITY REVIEW FOR BTC 04 May 2022 04 May 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 03 May 2022 03 May 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K RESULT OF AGM 29 Apr 2022 29 Apr 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA PLANS NEW R&D CENTRE IN MASSACHUSETTS 29 Apr 2022 29 Apr 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K FIRST QUARTER 2022 RESULTS 29 Apr 2022 29 Apr 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K ULTOMIRIS APPROVED IN THE US FOR ADULTS WITH GMG 28 Apr 2022 28 Apr 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU GRANTED BTD FOR HER2-LOW BREAST CANCER 27 Apr 2022 27 Apr 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K TREMELIMUMAB US PRIORITY REVIEW FOR IMFINZI COMBO 25 Apr 2022 25 Apr 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU GRANTED PRIORITY REVIEW FOR HER2M NSCLC 19 Apr 2022 19 Apr 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Apr 2022 01 Apr 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K ONDEXXYA APPROVED IN JAPAN FOR FXAI REVERSAL 29 Mar 2022 29 Mar 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K EVUSHELD APPROVED IN THE EU FOR COVID-19 28 Mar 2022 28 Mar 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 25 Mar 2022 25 Mar 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K EVUSHELD POSITIVE EU CHMP OPINION 24 Mar 2022 24 Mar 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K UPDATE ON CALLA PHASE III TRIAL OF CONCURRENT USE OF IMFINZI AND CHEMORADIOTHERA 24 Mar 2022 24 Mar 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K NOTICE OF AGM 23 Mar 2022 23 Mar 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K FORM 6-K 23 Mar 2022 23 Mar 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K SETTLEMENT OF PATENT LITIGATION FOR ULTOMIRIS 17 Mar 2022 17 Mar 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA APPROVED IN US FOR EARLY BREAST CANCER 14 Mar 2022 14 Mar 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K UPDATE ON US REVIEW OF FASENRA IN NASAL POLYPS 14 Mar 2022 14 Mar 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 09 Mar 2022 09 Mar 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 07 Mar 2022 07 Mar 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 01 Mar 2022 01 Mar 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Mar 2022 01 Mar 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA AND NEURIMMUNE CLOSE DEAL FOR NI006 01 Mar 2022 01 Mar 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K FILING OF FORM 20-F WITH SEC 23 Feb 2022 23 Feb 2022 001-11960
IRANNOTICE Open IRANNOTICE document View SEC filing for IRANNOTICE IRANNOTICE 22 Feb 2022 001-11960
20-F Open 20-F document | Open XBRL data View SEC filing for 20-F FORM 20F 22 Feb 2022 31 Dec 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K CHAIR SUCCESSION PLANNING UPDATE AND ANNUAL REPORT 22 Feb 2022 22 Feb 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU IMPROVES PFS AND OS IN HER2-LOW BC 22 Feb 2022 22 Feb 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K SAPHNELO APPROVED IN EU FOR SLE 16 Feb 2022 16 Feb 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA COMBO DELAYS PROGRESSION RISK IN PROSTATE 15 Feb 2022 15 Feb 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 11 Feb 2022 11 Feb 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K AZN: FULL YEAR AND Q4 2021 RESULTS 10 Feb 2022 10 Feb 2022 001-11960
SC 13G/A Open SC 13G/A document View SEC filing for SC 13G/A 07 Feb 2022 005-55247
SC 13G/A Open SC 13G/A document View SEC filing for SC 13G/A SEC SCHEDULE 13G 04 Feb 2022 005-55247
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Feb 2022 01 Feb 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI IMPROVES SURVIVAL IN BILIARY TRACT CANCER 19 Jan 2022 19 Jan 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI COMBO SHOWS UNPRECEDENTED SURVIVAL IN HCC 19 Jan 2022 19 Jan 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU GRANTED PRIORITY REVIEW FOR BREAST CANCER 18 Jan 2022 18 Jan 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA AND NEURIMMUNE SIGN DEAL FOR NI006 07 Jan 2022 07 Jan 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K TRANSFER OF RIGHTS TO EKLIRA, DUAKLIR COMPLETED 05 Jan 2022 05 Jan 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 04 Jan 2022 04 Jan 2022 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA AND IONIS CLOSE EPLONTERSEN DEAL 29 Dec 2021 29 Dec 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K ULTOMIRIS ACCEPTED FOR FDA PRIORITY REVIEW FOR GMG 21 Dec 2021 21 Dec 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K TEZSPIRE APPROVED IN THE US FOR SEVERE ASTHMA 20 Dec 2021 20 Dec 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K SAPHNELO RECOMMENDED FOR EU APPROVAL FOR SLE 20 Dec 2021 20 Dec 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 15 Dec 2021 15 Dec 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K EVUSHELD US FDA EUA 09 Dec 2021 09 Dec 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA, IONIS TO COLLABORATE ON EPLONTERSEN 07 Dec 2021 07 Dec 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K BLOCK LISTING INTERIM REVIEW 01 Dec 2021 01 Dec 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Dec 2021 01 Dec 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA GRANTED FDA PRIORITY REVIEW FOR OLYMPIA 30 Nov 2021 30 Nov 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 15 Nov 2021 15 Nov 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K AZN: YEAR TO DATE AND Q3 2021 RESULTS 12 Nov 2021 12 Nov 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Nov 2021 01 Nov 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA TO TRANSFER RIGHTS TO EKLIRA, DUAKLIR 01 Nov 2021 01 Nov 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI IMPROVED SURVIVAL IN BILIARY TRACT CANCER 25 Oct 2021 25 Oct 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K AZ RECOMMENDS ADS HOLDERS REJECT MINI-TENDER OFFER 18 Oct 2021 18 Oct 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI & TREMELIMUMAB IMPROVED OS IN LIVER CANCER 15 Oct 2021 15 Oct 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K AZD7442 PHIII TRIAL POSITIVE IN COVID OUTPATIENTS 12 Oct 2021 12 Oct 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU GRANTED BTD FOR BREAST CANCER 04 Oct 2021 04 Oct 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Oct 2021 01 Oct 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 30 Sep 2021 30 Sep 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA TO FULLY ACQUIRE CAELUM BIOSCIENCES 29 Sep 2021 29 Sep 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K SAPHNELO APPROVED IN JAPAN FOR SLE 28 Sep 2021 28 Sep 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA PROPEL TRIAL MEETS PRIMARY ENDPOINT 24 Sep 2021 24 Sep 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K BOARD COMMITTEE CHANGE 23 Sep 2021 23 Sep 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K NEW SUSTAINABILITY COMMITTEE OF THE BOARD 23 Sep 2021 23 Sep 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA $360M IRISH MANUFACTURING INVESTMENT 21 Sep 2021 21 Sep 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU REDUCED RISK OF DISEASE PROGRESSION BY 72% 20 Sep 2021 20 Sep 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI IMPROVES SURVIVAL IN NSCLC IN POSEIDON 09 Sep 2021 09 Sep 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K FIXED-DOSE COMBINATION OF ALBUTEROL AND BUDESONIDE (PT027) DEMONSTRATED SIGNIFIC 09 Sep 2021 09 Sep 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K ULTOMIRIS APPROVED IN EU FOR CHILDREN WITH PNH 03 Sep 2021 03 Sep 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Sep 2021 01 Sep 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K FORXIGA APPROVED IN JAPAN FOR CKD 26 Aug 2021 26 Aug 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K ALXN1840 WILSON PHASE III MET PRIMARY ENDPOINT 26 Aug 2021 26 Aug 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K UPDATE ON ULTOMIRIS PHASE III ALS TRIAL 20 Aug 2021 20 Aug 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K AZD7442 PROPHYLAXIS TRIAL MET PRIMARY ENDPOINT 20 Aug 2021 20 Aug 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 16 Aug 2021 16 Aug 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K UPDATE ON US REVIEW OF ROXADUSTAT 11 Aug 2021 11 Aug 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K FORXIGA APPROVED IN THE EU FOR CKD 09 Aug 2021 09 Aug 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU HEAD-TO-HEAD TRIAL MEETS PRIMARY ENDPOINT 09 Aug 2021 09 Aug 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 02 Aug 2021 02 Aug 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K SAPHNELO APPROVED IN THE US FOR SLE 02 Aug 2021 02 Aug 2021 001-11960
6-K/A Open 6-K/A document | Open XBRL data View SEC filing for 6-K/A FORM 6-K/A 30 Jul 2021 30 Jun 2021 001-11960
6-K Open 6-K document | Open XBRL data View SEC filing for 6-K FORM 6-K 30 Jul 2021 30 Jun 2021 001-11960
SC 13G Open SC 13G document View SEC filing for SC 13G SC 13G 27 Jul 2021
6-K Open 6-K document View SEC filing for 6-K ULTOMIRIS RECOMMENDED IN EU FOR CHILDREN WITH PNH 26 Jul 2021 26 Jul 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTORATE CHANGE 22 Jul 2021 22 Jul 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K FORM 6-K 21 Jul 2021 21 Jul 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 21 Jul 2021 21 Jul 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 21 Jul 2021 21 Jul 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K ACQUISITION OF ALEXION COMPLETED 21 Jul 2021 21 Jul 2021 001-11960
F-6EF Open F-6EF document View SEC filing for F-6EF REGISTRATION OF AMERICAN DEPOSITAR RECEIPT SHARES 19 Jul 2021 333-258002
6-K Open 6-K document View SEC filing for 6-K IMFINZI APPROVED IN CHINA FOR EXTENSIVE-STAGE SCLC 19 Jul 2021 19 Jul 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K STATUS ON US FDA ADVISORY COMMITTEE FOR ROXADUSTAT 16 Jul 2021 16 Jul 2021 001-11960
425 Open 425 document View SEC filing for 425 425 14 Jul 2021
425 Open 425 document View SEC filing for 425 425 14 Jul 2021
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA-ALEXION TRANSACTION CLEARED IN THE UK 14 Jul 2021 14 Jul 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K TEZEPELUMAB GRANTED FDA PRIORITY REVIEW FOR ASTHMA 08 Jul 2021 08 Jul 2021 001-11960
425 Open 425 document View SEC filing for 425 425 06 Jul 2021
425 Open 425 document View SEC filing for 425 425 06 Jul 2021
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA-ALEXION TRANSACTION CLEARED IN THE EU 06 Jul 2021 06 Jul 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Jul 2021 01 Jul 2021 001-11960
425 Open 425 document View SEC filing for 425 425 30 Jun 2021
11-K Open 11-K document View SEC filing for 11-K FORM 11-K 29 Jun 2021 31 Dec 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K FORXIGA RECOMMENDED IN EU FOR PATIENTS WITH CKD 28 Jun 2021 28 Jun 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K NIRSEVIMAB PHII/III TRIAL CONFIRMS SAFETY PROFILE 28 Jun 2021 28 Jun 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA APPROVED IN CHINA FOR PROSTATE CANCER 24 Jun 2021 24 Jun 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K ORPATHYS APPROVED IN CHINA FOR LUNG CANCER 23 Jun 2021 23 Jun 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K KOSELUGO APPROVED IN THE EU FOR CHILDREN WITH NF1 22 Jun 2021 22 Jun 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K UPDATE ON AZD7442 STORM CHASER TRIAL 15 Jun 2021 15 Jun 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K CALQUENCE HEAD-TO-HEAD RESULTS VERSUS IBRUTINIB 07 Jun 2021 07 Jun 2021 001-11960
425 Open 425 document View SEC filing for 425 425 04 Jun 2021
425 Open 425 document View SEC filing for 425 425 04 Jun 2021
6-K Open 6-K document View SEC filing for 6-K LYNPARZA REDUCED RECURRENCE RISK IN BREAST CANCER 04 Jun 2021 04 Jun 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA APPOINTS NEW CHIEF FINANCIAL OFFICER 04 Jun 2021 04 Jun 2021 001-11960
CERT Open CERT document View SEC filing for CERT 03 Jun 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K PUBLICATION OF FINAL TERMS 02 Jun 2021 02 Jun 2021 001-11960
8-A12B Open 8-A12B document View SEC filing for 8-A12B 8-A12B 01 Jun 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K BLOCK LISTING INTERIM REVIEW 01 Jun 2021 01 Jun 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Jun 2021 01 Jun 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K FORM 6-K 28 May 2021 28 May 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K TAGRISSOAPPROVED IN THE EU FOR THE ADJUVANT TREATMENT OFPATIENTS WITH EARLY-STAG 28 May 2021 28 May 2021 001-11960
424B2 Open 424B2 document View SEC filing for 424B2 424B2 27 May 2021 333-256406
425 Open 425 document View SEC filing for 425 425 27 May 2021
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA PRICES A EUR800M BOND OFFERING 27 May 2021 27 May 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA PRICES A $7BN BOND OFFERING 26 May 2021 26 May 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K FORM 6-K 26 May 2021 26 May 2021 001-11960
FWP Open FWP document View SEC filing for FWP FWP 26 May 2021 333-256406
FWP Open FWP document View SEC filing for FWP FWP 26 May 2021 333-256406
6-K Open 6-K document View SEC filing for 6-K EMTN PROGRAMME UPDATE - PUBLICATION OF PROSPECTUS 25 May 2021 25 May 2021 001-11960
425 Open 425 document View SEC filing for 425 425 24 May 2021
424B2 Open 424B2 document View SEC filing for 424B2 424B2 24 May 2021 333-256406
F-3ASR Open F-3ASR document View SEC filing for F-3ASR F-3ASR 24 May 2021 333-256406
6-K Open 6-K document View SEC filing for 6-K FORM 6-K 24 May 2021 24 May 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA COVID-19 VACCINE VAXZEVRIA AUTHORISED FOR EMERGENCY USE IN JAPAN 21 May 2021 21 May 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 18 May 2021 18 May 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K RESULT OF AGM 11 May 2021 11 May 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K SHAREHOLDERS VOTE IN FAVOUR OF ALEXION ACQUISITION 11 May 2021 11 May 2021 001-11960
425 Open 425 document View SEC filing for 425 425 07 May 2021
6-K Open 6-K document View SEC filing for 6-K IMFINZI + TREMELIMUMAB SHOWED SURVIVAL IN POSEIDON 07 May 2021 07 May 2021 001-11960
425 Open 425 document View SEC filing for 425 425 06 May 2021
425 Open 425 document View SEC filing for 425 425 05 May 2021
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 04 May 2021 04 May 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K FARXIGA APPROVED IN THE US FOR CKD 04 May 2021 04 May 2021 001-11960
425 Open 425 document View SEC filing for 425 425 30 Apr 2021
425 Open 425 document View SEC filing for 425 425 30 Apr 2021
425 Open 425 document View SEC filing for 425 425 30 Apr 2021
6-K Open 6-K document View SEC filing for 6-K AZN: FIRST QUARTER 2021 RESULTS 30 Apr 2021 30 Apr 2021 001-11960
425 Open 425 document View SEC filing for 425 425 29 Apr 2021
6-K Open 6-K document View SEC filing for 6-K NIRSEVIMAB PHASE III TRIAL MET PRIMARY ENDPOINT 26 Apr 2021 26 Apr 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K TAGRISSO ADJUVANT RECEIVES POSITIVE CHMP OPINION 26 Apr 2021 26 Apr 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K SELUMETINIB RECOMMENDED FOR EU APPROVAL IN NF1 26 Apr 2021 26 Apr 2021 001-11960
425 Open 425 document View SEC filing for 425 425 16 Apr 2021
425 Open 425 document View SEC filing for 425 425 16 Apr 2021
6-K Open 6-K document View SEC filing for 6-K US CLEARANCE OF PROPOSED ACQUISITION OF ALEXION 16 Apr 2021 16 Apr 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K TAGRISSO APPROVED IN CHINA IN EARLY LUNG CANCER 14 Apr 2021 14 Apr 2021 001-11960
424B3 Open 424B3 document View SEC filing for 424B3 424B3 13 Apr 2021 333-253315
EFFECT Open EFFECT document View SEC filing for EFFECT 12 Apr 2021 333-253315
425 Open 425 document View SEC filing for 425 425 12 Apr 2021
6-K Open 6-K document View SEC filing for 6-K FORM 6-K 12 Apr 2021 12 Apr 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K CIRCULAR AND NOTICE OF GENERAL MEETING 12 Apr 2021 12 Apr 2021 001-11960
425 Open 425 document View SEC filing for 425 425 12 Apr 2021
6-K Open 6-K document View SEC filing for 6-K UPDATE ON FARXIGA COVID-19 DARE-19 PHASE III TRIAL 12 Apr 2021 12 Apr 2021 001-11960
F-4/A Open F-4/A document View SEC filing for F-4/A F-4/A 09 Apr 2021 333-253315
CORRESP Open CORRESP document View SEC filing for CORRESP 08 Apr 2021
SC 13G Open SC 13G document View SEC filing for SC 13G SC 13G 08 Apr 2021
425 Open 425 document View SEC filing for 425 425 01 Apr 2021
425 Open 425 document View SEC filing for 425 425 01 Apr 2021
425 Open 425 document View SEC filing for 425 425 01 Apr 2021
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Apr 2021 01 Apr 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K NOTICE OF AGM 30 Mar 2021 30 Mar 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K FORM 6-K 30 Mar 2021 30 Mar 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 25 Mar 2021 25 Mar 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K AZD1222 US PH3 PRIMARY ANALYSIS CONFIRMS EFFICACY 25 Mar 2021 25 Mar 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA US VACCINE TRIAL MET PRIMARY ENDPOINT 22 Mar 2021 22 Mar 2021 001-11960
4 Open 4 document View SEC filing for 4 4 16 Mar 2021 15 Mar 2021 001-39067
6-K Open 6-K document View SEC filing for 6-K DIVESTMENT OF VIELA SHAREHOLDING COMPLETED 16 Mar 2021 16 Mar 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K US SUPPLY AGREEMENT FOR ADDITIONAL AZD7442 DOSES 16 Mar 2021 16 Mar 2021 001-11960
425 Open 425 document View SEC filing for 425 425 12 Mar 2021
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 09 Mar 2021 09 Mar 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K DESIGNATION OF EU HOME MEMBER STATE FOR EU SECURITIES REGULATION PURPOSES 04 Mar 2021 04 Mar 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K US COURT DECISION FAVOURS SYMBICORT PATENTS 03 Mar 2021 03 Mar 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K FURTHER UPDATE ON US REGULATORY REVIEW OF ROXADUSTAT IN ANAEMIA OF CHRONIC KIDNE 02 Mar 2021 02 Mar 2021 001-11960
UPLOAD Open UPLOAD document View SEC filing for UPLOAD 01 Mar 2021
6-K Open 6-K document View SEC filing for 6-K TRANSPARENCY DIRECTIVE VOTING RIGHTS AND CAPITAL 01 Mar 2021 01 Mar 2021 001-11960
425 Open 425 document View SEC filing for 425 425 26 Feb 2021
425 Open 425 document View SEC filing for 425 425 25 Feb 2021
6-K Open 6-K document View SEC filing for 6-K VOLUNTARY WITHDRAWAL OF IMFINZI INDICATION IN ADVANCED BLADDER CANCER IN THE US 22 Feb 2021 22 Feb 2021 001-11960
F-4 Open F-4 document View SEC filing for F-4 F-4 19 Feb 2021 333-253315
6-K Open 6-K document View SEC filing for 6-K LYNPARZA: IDMC RECOMMEND EARLY ANALYSIS OF OLYMPIA 17 Feb 2021 17 Feb 2021 001-11960
IRANNOTICE Open IRANNOTICE document View SEC filing for IRANNOTICE IRANNOTICE 16 Feb 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K FILING OF FORM 20-F WITH SEC 16 Feb 2021 16 Feb 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 16 Feb 2021 16 Feb 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K ANNUAL FINANCIAL REPORT 16 Feb 2021 16 Feb 2021 001-11960
20-F Open 20-F document | Open XBRL data View SEC filing for 20-F 20-F 16 Feb 2021 31 Dec 2020 001-11960
425 Open 425 document View SEC filing for 425 425 12 Feb 2021
425 Open 425 document View SEC filing for 425 425 11 Feb 2021
425 Open 425 document View SEC filing for 425 425 11 Feb 2021
425 Open 425 document View SEC filing for 425 425 11 Feb 2021
425 Open 425 document View SEC filing for 425 425 11 Feb 2021
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA NON-EXECUTIVE BOARD CHANGES 11 Feb 2021 11 Feb 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K AZN: FULL-YEAR 2020 RESULTS 11 Feb 2021 11 Feb 2021 001-11960
SC 13G Open SC 13G document View SEC filing for SC 13G SC 13G 10 Feb 2021
SC 13G/A Open SC 13G/A document View SEC filing for SC 13G/A SC 13G/A 10 Feb 2021
6-K Open 6-K document View SEC filing for 6-K DIVESTMENT OF CRESTOR IN EUROPE COMPLETED 10 Feb 2021 10 Feb 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K UPDATE ON KESTREL PHASE III TRIAL FOR IMFINZI 05 Feb 2021 05 Feb 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K FORXIGA APPROVED IN CHINA FOR HEART FAILURE 04 Feb 2021 04 Feb 2021 001-11960
SC 13G/A Open SC 13G/A document View SEC filing for SC 13G/A SEC SCHEDULE 13G 03 Feb 2021 005-55247
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Feb 2021 01 Feb 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA AGREES TO DIVEST VIELA SHAREHOLDING 01 Feb 2021 01 Feb 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K COVID-19 VACCINE AUTHORISED FOR USE BY THE EU 01 Feb 2021 01 Feb 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K COVID-19 VACCINE RECEIVES POSITIVE OPINION IN EU 29 Jan 2021 29 Jan 2021 001-11960
SC 13G/A Open SC 13G/A document View SEC filing for SC 13G/A 29 Jan 2021 005-55247
6-K Open 6-K document View SEC filing for 6-K BLOCK LISTING APPLICATION 26 Jan 2021 26 Jan 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K SYMBICORT APPROVED IN CHINA FOR MILD ASTHMA 26 Jan 2021 26 Jan 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K CALQUENCE APPROVED IN JAPAN FOR CLL 25 Jan 2021 25 Jan 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K CALQUENCE MET PRIMARY EFFICACY ENDPOINT IN HEAD-TO-HEAD TRIAL AGAINST IBRUTINIB 25 Jan 2021 25 Jan 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU APPROVED IN THE EU FOR BREAST CANCER 20 Jan 2021 20 Jan 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU APPROVED IN THE US FOR GASTRIC CANCER 19 Jan 2021 19 Jan 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI APPROVED IN THE EU FOR LESS-FREQUENT, FIXED- DOSE USE IN UNRESECTABLE NO 15 Jan 2021 15 Jan 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K FARXIGA GRANTED PRIORITY REVIEW IN THE US FOR THE TREATMENT OF PATIENTS WITH CHR 06 Jan 2021 06 Jan 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 04 Jan 2021 04 Jan 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K ATACAND DIVESTMENT TO CHEPLAPHARM IN MORE THAN 70 COUNTRIES COMPLETED 04 Jan 2021 04 Jan 2021 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA'S COVID-19 VACCINE AUTHORISED IN UK 30 Dec 2020 30 Dec 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA APPROVED IN JAPAN FOR THE TREATMENT OF ADVANCED OVARIAN, PROSTATE AND P 29 Dec 2020 29 Dec 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K TAGRISSO APPROVED IN THE US FOR THE ADJUVANT TREATMENT OF PATIENTS WITH EARLY-ST 21 Dec 2020 21 Dec 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K UPDATE ON US REGULATORY REVIEW OF ROXADUSTAT IN ANAEMIA OF CHRONIC KIDNEY DISEAS 21 Dec 2020 21 Dec 2020 001-11960
425 Open 425 document View SEC filing for 425 425 18 Dec 2020
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 17 Dec 2020 17 Dec 2020 001-11960
425 Open 425 document View SEC filing for 425 425 17 Dec 2020
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 16 Dec 2020 16 Dec 2020 001-11960
425 Open 425 document View SEC filing for 425 425 15 Dec 2020
6-K Open 6-K document View SEC filing for 6-K IMFINZI NEW DOSE RECEIVES POSITIVE EU CHMP OPINION 15 Dec 2020 15 Dec 2020 001-11960
425 Open 425 document View SEC filing for 425 425 14 Dec 2020
425 Open 425 document View SEC filing for 425 425 14 Dec 2020
425 Open 425 document View SEC filing for 425 425 14 Dec 2020
425 Open 425 document View SEC filing for 425 425 14 Dec 2020
6-K Open 6-K document View SEC filing for 6-K TRASTUZUMAB DERUXTECAN POSITIVE CHMP 14 Dec 2020 14 Dec 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K TRIXEO AEROSPHERE APPROVED IN THE EU FOR COPD 14 Dec 2020 14 Dec 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA TO ACQUIRE ALEXION PHARMACEUTICALS INC 14 Dec 2020 14 Dec 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K BLOCK LISTING INTERIM REVIEW 01 Dec 2020 01 Dec 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Dec 2020 01 Dec 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K CRESTOR TO BE DIVESTED TO GRUNENTHAL IN EUROPE 01 Dec 2020 01 Dec 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K FORXIGA APPROVED IN JAPAN FOR CHRONIC HEART FAILURE 30 Nov 2020 30 Nov 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K AZD1222 VACCINE EFFECTIVE AGAINST COVID-19 23 Nov 2020 23 Nov 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI NEW DOSING APPROVED IN THE US 20 Nov 2020 20 Nov 2020 001-11960
25-NSE Open 25-NSE document View SEC filing for 25-NSE 13 Nov 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K TEZEPELUMAB PHASE III TRIAL MET PRIMARY ENDPOINT 10 Nov 2020 10 Nov 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K CALQUENCE APPROVED IN THE EU FOR CLL 09 Nov 2020 09 Nov 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K BRILINTA APPROVED IN THE US IN STROKE 06 Nov 2020 06 Nov 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K AZN: YEAR-TO-DATE AND Q3 2020 RESULTS 05 Nov 2020 05 Nov 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K FORXIGA APPROVED IN THE EU FOR HEART FAILURE 05 Nov 2020 05 Nov 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA APPROVED IN THE EU AS 1ST-LINE MAINTENANCE TREATMENT WITH BEVACIZUMAB F 05 Nov 2020 05 Nov 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZAAPPROVED IN THE EU FOR THE TREATMENT OF BRCA- MUTATED METASTATIC CASTRAT 05 Nov 2020 05 Nov 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 02 Nov 2020 02 Nov 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K ATACAND TO BE DIVESTED TO CHEPLAPHARM IN MORE THAN 70 COUNTRIES 30 Oct 2020 30 Oct 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTORATE CHANGE 29 Oct 2020 29 Oct 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU GRANTED PRIORITY REVIEW IN THE US FOR THE TREATMENT OF HER2-POSITIVE MET 28 Oct 2020 28 Oct 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K FORXIGA CARDIOVASCULAR OUTCOMES BENEFIT APPROVED IN CHINA 28 Oct 2020 28 Oct 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K TAGRISSO ADJUVANT LUNG CANCER US PRIORITY REVIEW 20 Oct 2020 20 Oct 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K FORXIGA HF RECEIVES POSITIVE CHMP OPINION 19 Oct 2020 19 Oct 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K TRIXEO AEROSPHERE RECEIVES POSITIVE CHMP OPINION 19 Oct 2020 19 Oct 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K COVID-19 ANTIBODIES ADVANCE AND GET US FUNDING 13 Oct 2020 13 Oct 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K FARXIGA GRANTED US BTD IN CHRONIC KIDNEY DISEASE 02 Oct 2020 02 Oct 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Oct 2020 01 Oct 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTORATE CHANGE 25 Sep 2020 25 Sep 2020 001-11960
CERT Open CERT document View SEC filing for CERT 24 Sep 2020 001-11960
8-A12B Open 8-A12B document View SEC filing for 8-A12B 8-A12B 24 Sep 2020 001-11960
25 Open 25 document View SEC filing for 25 25 24 Sep 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR BRCA-MUTATED METASTATIC 21 Sep 2020 21 Sep 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZARECOMMENDED FOR APPROVAL IN EU BY CHMP AS 1ST-LINE MAINTENANCE TREATMENT 21 Sep 2020 21 Sep 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K TAGRISSO REDUCED THE RISK OF DISEASE RECURRENCE IN THE BRAIN BY 82% IN THE ADJUV 21 Sep 2020 21 Sep 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA TO LIST US ADR EQUITY AND ALL US DEBT SECURITIES ON NASDAQ 10 Sep 2020 10 Sep 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K FASENRA MET BOTH CO-PRIMARY ENDPOINTS OF REDUCED NASAL POLYP SIZE AND BLOCKAGE I 10 Sep 2020 10 Sep 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Sep 2020 01 Sep 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI APPROVED IN EU FOR SMALL CELL LUNG CANCER 01 Sep 2020 01 Sep 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K FARXIGA REDUCES CKD PROGRESSION AND RISK OF DEATH 01 Sep 2020 01 Sep 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K PHASE I CLINICAL TRIAL INITIATED FOR MONOCLONAL ANTIBODY COMBINATION FOR THE PRE 25 Aug 2020 25 Aug 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI APPROVED IN JAPAN FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG C 21 Aug 2020 21 Aug 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI GRANTED FDA PRIORITY REVIEW FOR LESS-FREQUENT, FIXED-DOSE USE 18 Aug 2020 18 Aug 2020 001-11960
CERT Open CERT document View SEC filing for CERT NYSE CERTIFICATION 12 Aug 2020 001-11960
8-A12B Open 8-A12B document View SEC filing for 8-A12B FORM 8-A12B 06 Aug 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K FORM 6-K 06 Aug 2020 06 Aug 2020 001-11960
424B2 Open 424B2 document View SEC filing for 424B2 FORM 424B2 05 Aug 2020 333-234586
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA PRICES A $3BN BOND ISSUE 04 Aug 2020 04 Aug 2020 001-11960
FWP Open FWP document View SEC filing for FWP FORM FWP 04 Aug 2020 333-234586
S-8 Open S-8 document View SEC filing for S-8 S-8 03 Aug 2020 333-240298
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 03 Aug 2020 03 Aug 2020 001-11960
FWP Open FWP document View SEC filing for FWP FORM FWP 03 Aug 2020 333-234586
424B2 Open 424B2 document View SEC filing for 424B2 FORM 424B2 03 Aug 2020 333-234586
6-K/A Open 6-K/A document | Open XBRL data View SEC filing for 6-K/A 6-K/A 31 Jul 2020 30 Jun 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K AZN: H1 2020 RESULTS 30 Jul 2020 30 Jul 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K TAGRISSO US BTD FOR EGFRM ADJUVANT LUNG CANCER 30 Jul 2020 30 Jul 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K BOARD COMMITTEE CHANGES 29 Jul 2020 29 Jul 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K FARXIGA DAPA-CKD TRIAL MET ALL ENDPOINTS 28 Jul 2020 28 Jul 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI RECOMMENDED FOR EU APPROVAL IN SCLC 27 Jul 2020 27 Jul 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K CALQUENCE RECEIVES POSITIVE CHMP OPINION FOR CLL 27 Jul 2020 27 Jul 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA ENTERS COLLABORATION IN ONCOLOGY 27 Jul 2020 27 Jul 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K BREZTRI AEROSPHERE APPROVED IN THE US FOR THE MAINTENANCE TREATMENT OF COPD 24 Jul 2020 24 Jul 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K HOLDING(S) IN COMPANY 22 Jul 2020 22 Jul 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K HOLDING(S) IN COMPANY 22 Jul 2020 22 Jul 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K HOLDING(S) IN COMPANY 21 Jul 2020 21 Jul 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K HOLDING(S) IN COMPANY 21 Jul 2020 21 Jul 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K COVID-19 VACCINE AZD1222 SHOWED ROBUST IMMUNE RESPONSES IN ALL PARTICIPANTS IN P 20 Jul 2020 20 Jul 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR DECLARATION 16 Jul 2020 16 Jul 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K BRILINTA GRANTED US FDA PRIORITY REVIEW FOR STROKE 09 Jul 2020 09 Jul 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA APPROVED IN THE EU FOR BRCA- MUTATED METASTATIC PANCREATIC CANCER 08 Jul 2020 08 Jul 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Jul 2020 01 Jul 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 30 Jun 2020 30 Jun 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K SELUMETINIB GRANTED ORPHAN DRUG DESIGNATION IN JAPAN FOR NEUROFIBROMATOSIS TYPE 30 Jun 2020 30 Jun 2020 001-11960
11-K Open 11-K document View SEC filing for 11-K 26 Jun 2020 31 Dec 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K HOLDING(S) IN COMPANY 17 Jun 2020 17 Jun 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K HOLDING(S) IN COMPANY 17 Jun 2020 17 Jun 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA TO SUPPLY EUROPE WITH UP TO 400 MILLION DOSES OF OXFORD UNIVERSITY'S 15 Jun 2020 15 Jun 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K EMTN PROGRAMME ROUTINE TECHNICAL UPDATE: PUBLICATION OF PROSPECTUS 11 Jun 2020 11 Jun 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Jun 2020 01 Jun 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K BLOCK LISTING INTERIM REVIEW 01 Jun 2020 01 Jun 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA RECOMMENDED FOR APPROVAL IN EU BY CHMP FOR BRCA-MUTATED METASTATIC PANC 01 Jun 2020 01 Jun 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K BRILINTA APPROVED IN THE US TO REDUCE THE RISK OF A FIRST HEART ATTACK OR STROKE 01 Jun 2020 01 Jun 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTUSIGNIFICANTLY IMPROVED TUMOUR RESPONSE RATE AND OVERALL SURVIVAL IN HER2- 29 May 2020 29 May 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI SHOWED A SUSTAINED OVERALL SURVIVAL BENEFIT IN 1ST-LINE EXTENSIVE-STAGE 29 May 2020 29 May 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K TAGRISSO DEMONSTRATED UNPRECEDENTED DISEASE-FREE SURVIVAL IN THE ADJUVANT TREATM 29 May 2020 29 May 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 26 May 2020 26 May 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU GRANTED ORPHAN DRUG DESIGNATION IN THE US FOR GASTRIC CANCER 22 May 2020 22 May 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA ADVANCES RESPONSE TO GLOBAL COVID-19 CHALLENGE AS IT RECEIVES FIRST 21 May 2020 21 May 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA APPROVED IN THE US FOR HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT 20 May 2020 20 May 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU US BREAKTHROUGH STATUS FOR LUNG CANCER 18 May 2020 18 May 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K BEVESPI AEROSPHERE APPROVED IN CHINA FOR COPD 18 May 2020 18 May 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU GRANTED BREAKTHROUGH THERAPY DESIGNATION IN THE US FOR HER2-POSITIVE MET 11 May 2020 11 May 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA RECOVERY OF GLOBAL RIGHTS TO BRAZIKUMAB (MEDI2070) FROM ALLERGAN COM 11 May 2020 11 May 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA APPROVED IN THE US AS 1ST-LINE MAINTENANCE TREATMENT WITH BEVACIZUMAB F 11 May 2020 11 May 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K FARXIGA APPROVED IN THE US FOR THE TREATMENT OF HEART FAILURE IN PATIENTS WITH H 06 May 2020 06 May 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 May 2020 01 May 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K RESULT OF AGM 29 Apr 2020 29 Apr 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K AZN: FIRST-QUARTER 2020 RESULTS 29 Apr 2020 29 Apr 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA DEMONSTRATED OVERALL SURVIVAL BENEFIT IN PHASE III PROFOUND TRIAL FOR B 24 Apr 2020 24 Apr 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K CHANGES TO ARRANGEMENTS FOR ANNUAL GENERAL MEETING 17 Apr 2020 17 Apr 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K KOSELUGO (SELUMETINIB) APPROVED IN US FOR PAEDIATRIC PATIENTS WITH NEUROFIBROMAT 14 Apr 2020 14 Apr 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K TAGRISSO PHASE III ADAURA TRIAL WILL BE UNBLINDED EARLY AFTER OVERWHELMING EFFIC 14 Apr 2020 14 Apr 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA DIVESTMENT OF MOVANTIK TO REDHILL BIOPHARMA COMPLETED 02 Apr 2020 02 Apr 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Apr 2020 01 Apr 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 31 Mar 2020 31 Mar 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K FARXIGA PHASE III DAPA-CKD TRIAL WILL BE STOPPED EARLY AFTER OVERWHELMING EFFICA 30 Mar 2020 30 Mar 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI APPROVED IN THE US FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER 30 Mar 2020 30 Mar 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 26 Mar 2020 26 Mar 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K LOKELMA APPROVED IN JAPAN FOR THE TREATMENT OF HYPERKALAEMIA 26 Mar 2020 26 Mar 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 20 Mar 2020 20 Mar 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA GRANTED ORPHAN DRUG DESIGNATION IN JAPAN FOR BRCA-MUTATED METASTATIC PA 19 Mar 2020 19 Mar 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI CONFIRMED A SUSTAINED OVERALL SURVIVAL BENEFIT IN FINAL ANALYSIS OF THE 17 Mar 2020 17 Mar 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K 6-K 12 Mar 2020 12 Mar 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K NOTICE OF AGM 12 Mar 2020 12 Mar 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K UPDATE ON PHASE III GY004 TRIAL FOR CEDIRANIB ADDED TO LYNPARZA IN PLATINUM-SENS 12 Mar 2020 12 Mar 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 10 Mar 2020 10 Mar 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K UPDATE ON PHASE III DANUBE TRIAL FOR IMFINZI AND TREMELIMUMAB IN UNRESECTABLE, S 06 Mar 2020 06 Mar 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K FILING OF FORM 20-F WITH SEC 04 Mar 2020 04 Mar 2020 001-11960
IRANNOTICE Open IRANNOTICE document View SEC filing for IRANNOTICE IRANNOTICE 03 Mar 2020 001-11960
20-F Open 20-F document | Open XBRL data View SEC filing for 20-F 20-F 03 Mar 2020 31 Dec 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K ANNUAL FINANCIAL REPORT 03 Mar 2020 03 Mar 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 02 Mar 2020 02 Mar 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA COMPLETES DIVESTMENT AGREEMENT WITH ATNAHS PHARMA FOR ESTABLISHED HY 02 Mar 2020 02 Mar 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 27 Feb 2020 27 Feb 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA DIVESTS GLOBAL RIGHTS TO MOVANTIK 25 Feb 2020 25 Feb 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 19 Feb 2020 19 Feb 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K AZN: FULL-YEAR AND Q4 2019 RESULTS 14 Feb 2020 14 Feb 2020 001-11960
4 Open 4 document View SEC filing for 4 4 07 Feb 2020 19 Dec 2019 001-35112
3 Open 3 document View SEC filing for 3 3 07 Feb 2020 19 Dec 2019 001-35112
SC 13D Open SC 13D document View SEC filing for SC 13D SC 13D 07 Feb 2020
EFFECT Open EFFECT document View SEC filing for EFFECT 06 Feb 2020 333-236014
SC 13G/A Open SC 13G/A document View SEC filing for SC 13G/A 05 Feb 2020 005-55247
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 03 Feb 2020 03 Feb 2020 001-11960
SC 13G Open SC 13G document View SEC filing for SC 13G SC 13G 30 Jan 2020
SC 13G/A Open SC 13G/A document View SEC filing for SC 13G/A SEC SCHEDULE 13G 27 Jan 2020 005-55247
6-K Open 6-K document View SEC filing for 6-K PHASE II DESTINY-GASTRIC01 TRIAL OF ENHERTU VERSUS CHEMOTHERAPY MET PRIMARY ENDP 27 Jan 2020 27 Jan 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA TO RECOVER THE GLOBAL RIGHTS TO BRAZIKUMAB (MEDI2070) FROM ALLERGAN 27 Jan 2020 27 Jan 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K BRILINTA MET PRIMARY ENDPOINT IN PHASE III THALES TRIAL IN STROKE 27 Jan 2020 27 Jan 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA DIVESTS RIGHTS TO ESTABLISHED HYPERTENSION MEDICINES 27 Jan 2020 27 Jan 2020 001-11960
F-6 Open F-6 document View SEC filing for F-6 FORM F-6 22 Jan 2020 333-236014
6-K Open 6-K document View SEC filing for 6-K LYNPARZA REGULATORY SUBMISSION GRANTED PRIORITY REVIEW IN THE US FOR HRR-MUTATED 21 Jan 2020 20 Jan 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI AND TREMELIMUMAB GRANTED ORPHAN DRUG DESIGNATION IN THE US FOR LIVER CAN 21 Jan 2020 20 Jan 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA REGULATORY SUBMISSION GRANTED PRIORITY REVIEW IN THE US FOR 1ST-LINE MA 13 Jan 2020 13 Jan 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K UPDATE ON PHASE III STRENGTH TRIAL FOR EPANOVA IN MIXED DYSLIPIDAEMIA 13 Jan 2020 13 Jan 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K LOKELMA APPROVED IN CHINA FOR THE TREATMENT OF ADULT PATIENTS WITH HYPERKALAEMIA 06 Jan 2020 06 Jan 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K FARXIGA GRANTED FDA PRIORITY REVIEW FOR PATIENTS WITH HEART FAILURE WITH REDUCED 06 Jan 2020 06 Jan 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 02 Jan 2020 02 Jan 2020 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZAAPPROVED IN THE US AS A 1ST-LINE MAINTENANCE TREATMENT OF GERMLINE BRCA- 30 Dec 2019 30 Dec 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA'S TRIPLE-COMBINATION THERAPY APPROVED IN CHINA FOR PATIENTS WITH COP 23 Dec 2019 23 Dec 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K ENHERTU (TRASTUZUMAB DERUXTECAN) APPROVED IN THE US FOR HER2-POSITIVE UNRESECTAB 23 Dec 2019 23 Dec 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA DIVESTS RIGHTS TO ARIMIDEX AND CASODEX IN EUROPE AND CERTAIN ADDITIO 20 Dec 2019 20 Dec 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K FDA PANEL BACKS LYNPARZA USE FOR PANCREATIC CANCER 17 Dec 2019 17 Dec 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K SEROQUEL RIGHTS AGREEMENT COMPLETE: EUROPE, RUSSIA 16 Dec 2019 16 Dec 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI APPROVED IN CHINA FOR THE TREATMENT OF UNRESECTABLE, STAGE III NON-SMALL 12 Dec 2019 12 Dec 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K TRASTUZUMAB DERUXTECAN ACHIEVED A TUMOUR RESPONSE RATE OF 60.9% IN PIVOTAL PHASE 11 Dec 2019 11 Dec 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA APPROVED IN CHINA AS A 1ST-LINE MAINTENANCE THERAPY IN BRCA-MUTATED ADV 05 Dec 2019 05 Dec 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA DIVESTS RIGHTS TO SEROQUEL AND SEROQUEL XR IN THE US AND CANADA 03 Dec 2019 03 Dec 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K BLOCK LISTING INTERIM REVIEW 02 Dec 2019 02 Dec 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 02 Dec 2019 02 Dec 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI GRANTED FDA PRIORITY REVIEW FOR THE TREATMENT OF PATIENTS WITH EXTENSIVE 29 Nov 2019 29 Nov 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K CALQUENCE APPROVED IN THE US FOR ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEM 21 Nov 2019 21 Nov 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K QTRILMET APPROVED IN THE EU FOR TREATMENT OF T2D 15 Nov 2019 15 Nov 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K FDA ACCEPTS REGULATORY SUBMISSION FOR SELUMETINIB 14 Nov 2019 14 Nov 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K ANIFROLUMAB DEMONSTRATED SUPERIORITY ACROSS MULTIPLE EFFICACY ENDPOINTS IN PATIE 12 Nov 2019 12 Nov 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K ROXADUSTAT PHASE III PROGRAMME POOLED ANALYSES SHOWED POSITIVE EFFICACY AND NO I 12 Nov 2019 12 Nov 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K ROXADUSTAT SIGNIFICANTLY INCREASED HAEMOGLOBIN LEVELS FOR CHRONIC KIDNEY DISEASE 08 Nov 2019 08 Nov 2019 001-11960
F-3ASR Open F-3ASR document View SEC filing for F-3ASR FORM F-3ASR 08 Nov 2019 333-234586
6-K Open 6-K document View SEC filing for 6-K CALQUENCE DATA TO SHOW IMPROVED PROGRESSION-FREE SURVIVAL IN PHASE III FRONT-LIN 06 Nov 2019 06 Nov 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Nov 2019 01 Nov 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA DIVESTS RIGHTS TO SEROQUEL AND SEROQUEL XR IN EUROPE AND RUSSIA 30 Oct 2019 30 Oct 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI AND IMFINZI PLUS TREMELIMUMAB DELAYED 28 Oct 2019 28 Oct 2019 001-11960
SC 13D Open SC 13D document View SEC filing for SC 13D SC 13D 25 Oct 2019
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA YEAR-TO-DATE AND Q3 2019 RESULTS 24 Oct 2019 24 Oct 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K FARXIGA APPROVED IN THE US TO REDUCE THE RISK OF HOSPITALISATION FOR HEART FAILU 21 Oct 2019 21 Oct 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K TRASTUZUMAB DERUXTECAN GRANTED FDA PRIORITY REVIEW FOR TREATMENT OF PATIENTS WIT 17 Oct 2019 17 Oct 2019 001-11960
4 Open 4 document View SEC filing for 4 FORM 4 SUBMISSION 09 Oct 2019 07 Oct 2019 001-39067
3/A Open 3/A document View SEC filing for 3/A FORM 3/A SUBMISSION 09 Oct 2019 02 Oct 2019 001-39067
6-K Open 6-K document View SEC filing for 6-K HOLDING(S) IN COMPANY 04 Oct 2019 04 Oct 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K HOLDING(S) IN COMPANY 04 Oct 2019 04 Oct 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K FASENRA APPROVED IN THE US FOR SELF-ADMINISTRATION 04 Oct 2019 04 Oct 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR DECLARATION 03 Oct 2019 03 Oct 2019 001-11960
3 Open 3 document View SEC filing for 3 FORM 3 SUBMISSION 02 Oct 2019 02 Oct 2019 001-39067
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Oct 2019 01 Oct 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA DIVESTS RIGHTS FOR LOSEC TO CHEPLAPHAR 01 Oct 2019 01 Oct 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K UPDATE ON US REGULATORY REVIEW OF PT010 IN COPD 01 Oct 2019 01 Oct 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA MORE THAN DOUBLED THE TIME WITHOUT RADIOGRAPHIC DISEASE PROGRESSION IN 30 Sep 2019 30 Sep 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA IMPROVED THE TIME WOMEN LIVED WITHOUT DISEASE PROGRESSION TO 22 MONTHS 30 Sep 2019 30 Sep 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K TAGRISSO IS THE ONLY 1ST-LINE TREATMENT FOR EGFR-MUTATED NON-SMALL CELL LUNG CAN 30 Sep 2019 30 Sep 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K QTRILMET RECOMMENDED FOR APPROVAL IN EU BY CHMP 23 Sep 2019 23 Sep 2019 001-11960
25-NSE Open 25-NSE document View SEC filing for 25-NSE 18 Sep 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA AMENDS COLLABORATION WITH IRONWOOD FOR LINZESS IN CHINA 18 Sep 2019 18 Sep 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI IS FIRST IMMUNOTHERAPY TO SHOW BOTH SIGNIFICANT SURVIVAL BENEFIT AND IMP 09 Sep 2019 09 Sep 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K TAGRISSO APPROVED IN CHINA AS A 1ST-LINE TREATMENT FOR EGFR-MUTATED NON-SMALL CE 04 Sep 2019 04 Sep 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 03 Sep 2019 03 Sep 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K DETAILED RESULTS FROM PHASE III DAPA-HF TRIAL SHOWED FARXIGA SIGNIFICANTLY REDUC 03 Sep 2019 03 Sep 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K BRILINTA REDUCED THE RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH CORONARY ART 03 Sep 2019 03 Sep 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K ANIFROLUMAB PHASE III TRIAL MEETS PRIMARY ENDPOINT IN SYSTEMIC LUPUS ERYTHEMATOS 29 Aug 2019 29 Aug 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K BREZTRI AEROSPHERE PHASE III ETHOS TRIAL MET ITS PRIMARY ENDPOINT IN CHRONIC OBS 28 Aug 2019 28 Aug 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K FASENRA GRANTED US ORPHAN DRUG DESIGNATION FOR EOSINOPHILIC OESOPHAGITIS 28 Aug 2019 28 Aug 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K ROXADUSTAT APPROVED IN CHINA FOR THE TREATMENT OF ANAEMIA IN NON-DIALYSIS-DEPEND 22 Aug 2019 22 Aug 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA AGREES TO BUY US FDA PRIORITY REVIEW 22 Aug 2019 22 Aug 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K UPDATE ON THE PHASE III NEPTUNE TRIAL 21 Aug 2019 21 Aug 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K FARXIGA MET PRIMARY ENDPOINT IN LANDMARK PHASE III 20 Aug 2019 20 Aug 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTORATE CHANGE 19 Aug 2019 19 Aug 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K CALQUENCE GRANTED US BREAKTHROUGH THERAPY DESIGNATION 14 Aug 2019 14 Aug 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA PHASE III PAOLA-1 TRIAL MET PRIMARY ENDPOINT 14 Aug 2019 14 Aug 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K TAGRISSO SIGNIFICANTLY IMPROVES OVERALL SURVIVAL 09 Aug 2019 09 Aug 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA PHASE III PROFOUND TRIAL IN HRR* 07 Aug 2019 07 Aug 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K FORXIGA LABEL UPDATED IN THE EU IN TYPE-2 DIABETES 05 Aug 2019 05 Aug 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Aug 2019 01 Aug 2019 001-11960
6-K Open 6-K document | Open XBRL data View SEC filing for 6-K 6-K 25 Jul 2019 30 Jun 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K UPDATE ON US REGULATORY DECISION FOR FARXIGA 15 Jul 2019 15 Jul 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI GRANTED US ORPHAN DRUG DESIGNATION FOR SMALL CELL LUNG CANCER 12 Jul 2019 12 Jul 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K FASENRA RECEIVES POSITIVE EU CHMP OPINION FOR SELF 01 Jul 2019 01 Jul 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Jul 2019 01 Jul 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K FORXIGA RECEIVES POSITIVE EU CHMP OPINION FOR 01 Jul 2019 01 Jul 2019 001-11960
11-K Open 11-K document View SEC filing for 11-K 27 Jun 2019 31 Dec 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K IMFINZI IMPROVES OVERALL SURVIVAL AT INTERIM 27 Jun 2019 27 Jun 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K BREZTRI AEROSPHERE (PT010) APPROVED IN JAPAN FOR PATIENTS WITH CHRONIC OBSTRUCTI 19 Jun 2019 19 Jun 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA APPROVED IN JAPAN FOR 1ST-LINE MAINTENANCE THERAPY IN BRCA-MUTATED ADVA 19 Jun 2019 19 Jun 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K BEVESPI AEROSPHERE APPROVED BY THE JAPANESE MINISTRY OF HEALTH, LABOUR AND WELFA 19 Jun 2019 19 Jun 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA APPROVED IN THE EU FOR 1ST-LINE 18 Jun 2019 18 Jun 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K CALQUENCE SIGNIFICANTLY PROLONGED THE TIME PATIENT 17 Jun 2019 17 Jun 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K PUBLICATION OF A PROSPECTUS 12 Jun 2019 12 Jun 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K CALQUENCE PHASE III ELEVATE-TN TRIAL MET PRIMARY 06 Jun 2019 06 Jun 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K BLOCK LISTING INTERIM REVIEW 03 Jun 2019 03 Jun 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 03 Jun 2019 03 Jun 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA NEARLY DOUBLED THE TIME PATIENTS LIVED WITHOUT DISEASE PROGRESSION FROM 03 Jun 2019 03 Jun 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K POOLED ANALYSES OF THE ROXADUSTAT GLOBAL PHASE III 10 May 2019 10 May 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 08 May 2019 08 May 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR DECLARATION 08 May 2019 08 May 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K TRASTUZUMAB DERUXTECAN DEMONSTRATED CLINICALLY 08 May 2019 08 May 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K CALQUENCE PHIII ASCEND TRIAL MET PRIMARY ENDPOINT 07 May 2019 07 May 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K QTERNMET XR APPROVED IN THE US FOR TYPE-2 DIABETES 03 May 2019 03 May 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 May 2019 01 May 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 01 May 2019 01 May 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA RECEIVES POSITIVE EU CHMP OPINION FOR 1ST 29 Apr 2019 29 Apr 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K RESULT OF AGM 26 Apr 2019 26 Apr 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K AZN: Q1 2019 RESULTS 26 Apr 2019 26 Apr 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA APPROVED IN EU FOR THE TREATMENT OF GERMLINE BRCA-MUTATED HER2-NEGATIVE 10 Apr 2019 10 Apr 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K HOLDING(S) IN COMPANY 04 Apr 2019 04 Apr 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 03 Apr 2019 03 Apr 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 02 Apr 2019 02 Apr 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Apr 2019 01 Apr 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K SELUMETINIB GETS BREAKTHROUGH THERAPY DESIGNATION 01 Apr 2019 01 Apr 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K RESULTS OF PLACING 29 Mar 2019 29 Mar 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K AZ AND DAIICHI SANKYO ENTER COLLABORATION IN NOVEL 29 Mar 2019 29 Mar 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K FORXIGA APPROVED IN JAPAN FOR TYPE-1 DIABETES 27 Mar 2019 27 Mar 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K FORXIGA APPROVED IN EUROPE FOR TYPE-1 DIABETES 25 Mar 2019 25 Mar 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K US FDA GRANTS SARACATINIB ODD FOR IPF 18 Mar 2019 18 Mar 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K NOTICE OF AGM 14 Mar 2019 14 Mar 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K 6-K 14 Mar 2019 14 Mar 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 12 Mar 2019 12 Mar 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K FILING OF FORM 20-F WITH SEC 06 Mar 2019 06 Mar 2019 001-11960
IRANNOTICE Open IRANNOTICE document View SEC filing for IRANNOTICE IRANNOTICE 05 Mar 2019 001-11960
20-F Open 20-F document | Open XBRL data View SEC filing for 20-F 20-F 05 Mar 2019 31 Dec 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K ANNUAL FINANCIAL REPORT 05 Mar 2019 05 Mar 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Mar 2019 01 Mar 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA RECEIVES POSITIVE EU CHMP OPINION 01 Mar 2019 01 Mar 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA SIGNIFICANTLY DELAYED DISEASE PROGRESSION 26 Feb 2019 26 Feb 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K BRILINTA'S PHIII THEMIS TRIAL MET PRIMARY ENDPOINT 25 Feb 2019 25 Feb 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA FULL-YEAR AND Q4 2018 RESULTS 14 Feb 2019 14 Feb 2019 001-11960
SC 13G/A Open SC 13G/A document View SEC filing for SC 13G/A SEC SCHEDULE 13G 12 Feb 2019 005-55247
6-K Open 6-K document View SEC filing for 6-K US FDA GRANTS FASENRA ORPHAN DRUG DESIGNATION 06 Feb 2019 06 Feb 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K US FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION 05 Feb 2019 05 Feb 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K EMA GRANTS PRIME ELIGIBILITY FOR MEDI8897 05 Feb 2019 05 Feb 2019 001-11960
SC 13G/A Open SC 13G/A document View SEC filing for SC 13G/A 04 Feb 2019 005-55247
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Feb 2019 01 Feb 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K FORXIGA RECEIVES POSITIVE EU CHMP OPINION 01 Feb 2019 01 Feb 2019 001-11960
SC 13G Open SC 13G document View SEC filing for SC 13G SC 13G 30 Jan 2019
6-K Open 6-K document View SEC filing for 6-K COMPLETION OF DIVESTMENT OF US SYNAGIS RIGHTS 25 Jan 2019 25 Jan 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA ANNOUNCES ORGANISATIONAL CHANGES 07 Jan 2019 07 Jan 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 02 Jan 2019 02 Jan 2019 001-11960
6-K Open 6-K document View SEC filing for 6-K BEVESPI AEROSPHERE APPROVED IN THE EU FOR COPD 20 Dec 2018 20 Dec 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA MEETS PRIMARY ENDPOINT IN SOLO-3 TRIAL 20 Dec 2018 20 Dec 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K PHASE III ROCKIES AND OLYMPUS ROXADUSTAT TRIALS 20 Dec 2018 20 Dec 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K FDA APPROVES LYNPARZA AS 1L MAINTENANCE THERAPY 19 Dec 2018 19 Dec 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K ROXADUSTAT APPROVED IN CHINA FOR THE TREATMENT OF ANAEMIA IN CHRONIC KIDNEY DISE 18 Dec 2018 18 Dec 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTORATE CHANGE 14 Dec 2018 14 Dec 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K UPDATE ON THE PHASE III EAGLE TRIAL OF IMFINZI 07 Dec 2018 07 Dec 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K DIVESTMENT OF RIGHTS TO COVIS COMPLETED 06 Dec 2018 06 Dec 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 04 Dec 2018 04 Dec 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K BLOCK LISTING INTERIM REVIEW 03 Dec 2018 03 Dec 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 03 Dec 2018 03 Dec 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K GRUNENTHAL AGREEMENT FOR NEXIUM VIMOVO COMPLETED 03 Dec 2018 03 Dec 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K US FDA GRANTS FASENRA ODD FOR EGPA 26 Nov 2018 26 Nov 2018 001-11960
25-NSE Open 25-NSE document View SEC filing for 25-NSE 16 Nov 2018 001-11960
25-NSE Open 25-NSE document View SEC filing for 25-NSE 16 Nov 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA PROVIDES UPDATE ON PHASE III MYSTIC 16 Nov 2018 16 Nov 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA TO DIVEST US SYNAGIS RIGHTS TO SOBI 13 Nov 2018 13 Nov 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K US FDA ACCEPTS REGULATORY SUBMISSION FOR LYNPARZA 13 Nov 2018 13 Nov 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K FARXIGA SIGNIFICANTLY REDUCED HOSPITALISATION FOR 13 Nov 2018 13 Nov 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K AZN: YEAR-TO-DATE AND Q3 2018 RESULTS 08 Nov 2018 08 Nov 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K DIVESTMENT OF RIGHTS TO COVIS PHARMA 06 Nov 2018 06 Nov 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Nov 2018 01 Nov 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K ADDITIONAL FINANCIAL INFORMATION-GRUNENTHAL DEAL 31 Oct 2018 31 Oct 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K GRUNENTHAL AGREEMENT FOR RIGHTS TO NEXIUM VIMOVO 30 Oct 2018 30 Oct 2018 001-11960
SC 13D Open SC 13D document View SEC filing for SC 13D SC 13D 29 Oct 2018
4 Open 4 document View SEC filing for 4 FORM 4 SUBMISSION 24 Oct 2018 22 Oct 2018 001-38697
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA EXTENDS INNATE PHARMA COLLABORATION 23 Oct 2018 23 Oct 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K LYNPARZA SHOWS 70% REDUCTION IN PFS OVARIAN CANCER 22 Oct 2018 22 Oct 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K CHMP POSITIVE OPINION BEVESPI AEROSPHERE 19 Oct 2018 19 Oct 2018 001-11960
3 Open 3 document View SEC filing for 3 FORM 3 SUBMISSION 17 Oct 2018 17 Oct 2018 001-38697
6-K Open 6-K document View SEC filing for 6-K FDA ORPHAN DRUG FOR LYNPARZA IN PANCREATIC CANCER 16 Oct 2018 16 Oct 2018 001-11960
SC 13D/A Open SC 13D/A document View SEC filing for SC 13D/A SC 13D/A 12 Oct 2018
SC 13D Open SC 13D document View SEC filing for SC 13D SC 13D 05 Oct 2018
4 Open 4 document View SEC filing for 4 FORM 4 SUBMISSION 02 Oct 2018 28 Sep 2018 001-38670
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Oct 2018 01 Oct 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K ATACAND AGREEMENT WITH CHEPLAPHARM COMPLETED 01 Oct 2018 01 Oct 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K PREVIOUS ANNOUNCEMENT REGARDING APPOINTMENT OF NED 28 Sep 2018 28 Sep 2018 001-11960
3 Open 3 document View SEC filing for 3 FORM 3 SUBMISSION 25 Sep 2018 25 Sep 2018 001-38670
6-K Open 6-K document View SEC filing for 6-K OVERALL SURVIVAL DATA FOR IMFINZI: STAGE III NSCLC 25 Sep 2018 25 Sep 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K EMA APPROVES AZ'S IMFINZI FOR STAGE III NSCLC 24 Sep 2018 24 Sep 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K FARXIGA GETS POSITIVE RESULT IN DECLARE-TIMI 58 24 Sep 2018 24 Sep 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K FDA APPROVES AZS LUMOXITI IN HAIRY CELL LEUKAEMIA 14 Sep 2018 14 Sep 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K TEZEPELUMAB FDA BREAKTHROUGH THERAPY DESIGNATION 07 Sep 2018 07 Sep 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K DIRECTORATE CHANGE 06 Sep 2018 06 Sep 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 04 Sep 2018 04 Sep 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA UPDATE ON ANIFROLUMAB IN SLE 31 Aug 2018 31 Aug 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K EC APPROVES BYDUREON BCISE DEVICE FOR T2 DIABETES 30 Aug 2018 30 Aug 2018 001-11960
CERT Open CERT document View SEC filing for CERT NYSE CERTIFICATION - ASTRAZENECA PLC 23 Aug 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K ASTRAZENECA PIIIB TRIAL UPDATE FOR BEVESPI IN COPDASTRAZENECA PIIIB TRIAL UPDATE 23 Aug 2018 23 Aug 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K AZ'S TAGRISSO APPROVED IN JAPAN FOR 1ST-LINE NSCLC 21 Aug 2018 21 Aug 2018 001-11960
8-A12B Open 8-A12B document View SEC filing for 8-A12B FORM 8-A12B 17 Aug 2018 001-11960
6-K Open 6-K document View SEC filing for 6-K FORM 6-K 17 Aug 2018 17 Aug 2018 001-11960

About this filer

ASTRAZENECA PLC files with the SEC under CIK 0000901832. This page aggregates EDGAR filings and related ownership activity.

Industry: Pharmaceutical Preparations.

FAQ

What is a CIK?
A Central Index Key (CIK) is a unique identifier assigned by the SEC to each filer.
Why are some filings missing?
New filings appear as the SEC updates EDGAR, and older records can vary by availability.
How often is this page updated?
Updates follow new EDGAR submissions and periodic data refreshes.

Related pages